Behavioral and Cytological Differences between Two Parkinson's Disease Experimental Models

*Maria Rosa Avila-Costa, José Luis Ordoñez-Librado, Ana Luisa Gutierréz-Valdez, Javier Sanchez-Betancourt, Ma Teresa Ibarra-Gutiérrez, Patricia E. Reyna-Velázquez, Verónica Anaya-Martínez, Cesar Alfonso Garcia Caballero, Enrique Montiel-Flores, Claudia Dorado-Martínez, Leonardo Reynoso-Erazo, Vianey Rodríguez-Lara and Rocío Tron-Alvarez*

## **Abstract**

The knowledge about the biochemical and behavioral changes in humans with PD has allowed proposing animal models for its study; however, the results obtained so far have been heterogeneous. Recently, we established a novel PD model in rodents by manganese chloride (MnCl2) and manganese acetate (Mn (OAc)3) mixture inhalation. After inhaling, the rodents presented bilateral loss of SNc dopaminergic neurons. Later, we conclude that the alterations are of dopamine origin since L-DOPA reverted the alterations. After six months, SNc significantly reduced the number of cells, and striatal dopamine content decreased by 71%. The animals had postural instability, action tremor, and akinesia; these symptoms improved with L-DOPA, providing evidence that Mn mixture inhalation induces comparable alterations that those in PD patients. Thus, this study aimed to compare the alterations in two different PD experimental models: 6-OHDA unilateral lesion and Mn mixture inhalation through open field test, rotarod performance and the number of SNc dopaminergic neurons. The results show that the Mn-exposed animals have motor alterations and bilateral and progressive SNc neurons degeneration; in contrast, in the 6-OHDA model, the neuronal loss is unilateral and acute, demonstrating that the Mn exposure model better recreates the characteristics observed in PD patients.

**Keywords:** Mn inhalation, Parkinson's disease experimental models, motor behavior, TH immunohistochemistry, rotarod performance

## **1. Introduction**

Parkinson's disease (PD) is a neurodegenerative disorder with movement abnormalities, which include tremor, rigidity, akinesia, bradykinesia, masked face, and postural and gait abnormalities [1] involving the continued dopaminergic cell loss projecting from the substantia nigra compacta (SNc) to the striatum. Within neurodegenerative diseases, it is the second most frequent, resulting in motor disorders, abnormal dopamine signaling, and dopamine cell death [2, 3].

While its causes are still not fully understood, experimental models have postulated essential evidence. Based on clinical and experimental findings, PD was the first neurodegenerative disorder to be modeled and treated by neurotransmitter replacement therapy [4].

When selecting an animal PD model, one has to be considering the differences and similarities between humans and animals' behavior, physiology, and anatomy. The prevailing models have helped understand the disease's causes and compromised resources for new treatment approaches [5]. Nevertheless, the dopamine deafferentation simulated in animals, by the wide variety of neurotoxins or genetic manipulations, some PD models destroy the dopaminergic neurons rapidly and not progressively. In genetic PD models, the dopaminergic loss, while more progressive, is limited in amount or may not occur at all [5, 6].

The typical PD models (**Table 1**) induce nigrostriatal dopaminergic cell loss, frequently with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 6-hydroxydopamine (6-OHDA), rotenone or paraquat [4, 6–9]. It is known that these models induce mitochondrial dysfunction and/or reactive oxygen species, but none completely simulate the pathology and symptoms seen in humans [7, 9]. 6-OHDA and MPTP are neurotoxins that rapidly and selectively destroy the dopaminergic neurons (within 1–3 days), while PD pathogenesis obeys a progressive progression over decades [4, 10].

The consequences of manganese (Mn) as a PD model have been investigated since its toxicity (known as manganism) is related to extrapyramidal motor system symptoms [11–14].

For a long time, there has been some controversy about Mn-induced dopaminergic alterations; whereas some researchers reported that Mn alters dopaminergic innervation, particularly in the basal ganglia, and produces Parkinson-like disorder [14–18],


#### **Table 1.** *Some PD experimental models.*

*Behavioral and Cytological Differences between Two Parkinson's Disease Experimental Models DOI: http://dx.doi.org/10.5772/intechopen.108268*

many authors suggested that Mn neurotoxicity is unlike from PD in symptoms, pathology, and etiology [18, 19], particularly in the evident preservation of SNc dopaminergic somas [20–24].

We recently established an innovative PD model in mice [25, 26] and rats [27] by the inhalation of the mixture of two Mn compounds, Manganese chloride (MnCl2) and Manganese acetate (Mn(OAc)3). After Mn mixture inhalation, the rodents presented a significant loss of SNc dopaminergic neurons (67.58%) [26]. Later, we determine whether L-DOPA treatment improves the behavior to ensure that the alterations are of dopamine origin [27, 28]. Consequently, after six months of Mn compounds inhalation, striatal dopamine concentration decreased by 71%, and SNc showed a significant reduction in the number of TH+ neurons. The animals presented action tremor and postural instability, which were improved with L-DOPA—suggesting that MnCl2/Mn (OAc)3 mixture inhalation induces comparable symptoms and neurochemical and cellular alterations to those observed in PD patients, providing a valuable model for the study of this disease [25–28]. Additionally, Mn inhalation is progressive and bilateral, making it more reliable. Thus, this study aimed to compare motor alterations in two different PD experimental models: 6-OHDA unilateral lesion (the most common used PD-experimental model [29] and MnCl2/Mn(OAc)3 mixture inhalation through open field test determining: walking distance (ambulation), rearing and walking speed, freezing time, rotarod performance and bradykinesia and counting the number of TH neurons in the SNc.

## **2. Methods**

Male adult Wistar rats (starting weight 180–200 g) were placed during the recovery from the 6-OHDA surgery; two weeks after the surgery or Mn mixture inhalation, they were accommodated in groups of four with an inverted dark-light cycle (12:12 h) and fed with Purina Rat Chow and water *ad libitum*. Body weight was recorded daily. The experimental protocol follows the National Institute of Health Guide for the Care and Use of Laboratory Animals (NIH Publications No. 80-23) revised in 1996 and the Rules for Research in Health Matters (Mexico). We strive to limit the animals' amount and their distress. Rotarod performance and open field were tested before the lesion or Mn inhalations as preliminary parameters (average condition) of each rat's motor coordination, postural balance, and muscle rigidity to follow up on their performance throughout the experiment. The rats were first tested in the rotarod and trained to remain on the rod at 5 rpm and 10 rpm for 2 min, discarding those that, after three consecutive days, were unable to stay on the rod [30].

#### **2.1 Stereotactic surgery**

The rats were anesthetized with sodium pentobarbitone (35 mg/kg, intraperitoneal) and placed in a stereotaxic apparatus (David Kopf Instruments, Tujunga, CA). They were injected with 4 ml of saline solution containing 8 mg of 6-OHDA (Sigma Chemical Company, Mexico) and 0.2 mg of ascorbic acid (n = 6) into the left medial forebrain bundle (MFB). For the unilateral lesion, the stereotaxic coordinates were as follows: AP=–6.1 mm anterior to the interaural line; L = 1.6 mm lateral to bregma; and V = – 8.1 mm vertical from dura according to Paxinos and Watson [31]. A sham lesion was made with the vehicle using the exact coordinates (n = 6, control group). The injections were administered over a 4-min period using a Hamilton syringe attached to a glass micropipette with a 20–50 mm tip diameter.

## **2.2 Manganese inhalation**

Inhalations were performed as described by [25, 32]. Six rats were placed in an acrylic chamber inhaling 0.04 M MnCl2 and 0.02 M Mn (OAc)3 one hour thrice a week for six months. Six control rats inhaled only the vehicle—deionized water for the same period. Inhalations were performed in closed acrylic boxes (40 cm wide/70 cm long and 25 cm high) connected to an ultra-nebulizer (Shinmed, Taiwan) with 10 l/min continuous flux. The ultra-nebulizer produces droplets in a 0.5–5 mm range. A trap for the vapor was on the contrary side with a sodium bicarbonate solution to precipitate the remaining metal. During exposures, animals were constantly monitored for respiration rate, depth, and regularity. The exposure system was continuously monitored for temperature, oxygen level, and Mn concentration [25, 32].

## **2.3 Motor behavior**

### *2.3.1 Rotarod performance*

The rotarod consists of a four-lane rotating rod (diameter 7.5 cm) and infrared beams to detect the moment of fall. The rat's body was placed perpendicular to the rotating axis and the head against the direction of the rotation; the animal must move forward to stay on the rod. Each rat was tested for about 15 min between the different testing speeds, thus reducing stress and fatigue. The rats were trained twice on the rotarod at the constant rate of 5 and 10 rpm for two min during three consecutive days before the performance evaluation. In the evaluating session, the rats were placed on the rod, and their performance was tested at different constant speeds (5, 10, 15, 20, and 25 rpm) for a maximum of two min at each rate. All rats were video recorded while on the rod to assess their motor coordination and posture [30]. Control, 6-OHDA-lesioned and Mn-inhaled groups were evaluated before the experimental procedures and after three and six months.

#### *2.3.2 Open field test*

The rats' behavior in the open field was evaluated before the experimental procedures and after three and six months. The rat was placed in the center of a square arena (80 × 80 cm) with 40 cm high, opaque black walls in a quiet, red-light-illuminated room. The motor behavior was video recorded for 20 min. The geometrical coordinates of the rat position in the arena were measured from the recorded videos to obtain the spatiotemporal sequence of the movements. The following behavioral parameters were measured: walking distance (ambulation), rearing, and walking speed. Bradykinesia was estimated by the reduction in walking speed assessed by the time taken by the rat to move from one corner of the open field to the next with relative speed. The arena was cleaned with a water/alcohol (70%) solution before every behavioral testing to avoid a possible bias due to odors and residues left by rats tested earlier [30]. All experiments were carried out from 11:00 a.m. to 3:00 p.m.

The times the rat passed through the center of the arena (central lines; **Figure 1**) of the open field were counted and multiplied by the distance (115 cm).

#### **2.4 Tyrosine hydroxylase (TH) immunocytochemistry**

After six months, for the immunohistochemical study, the rats were deeply anesthetized under pentobarbitone anesthesia (35 mg/kg, i.p.) after the last behavioral

*Behavioral and Cytological Differences between Two Parkinson's Disease Experimental Models DOI: http://dx.doi.org/10.5772/intechopen.108268*

## **Figure 1.** *Open field test. Rat trace in the center of the arena.*

test and perfused transcardially with 120 ml of 0.9% saline, followed by 300 ml of 4% paraformaldehyde.

Coronal sections (50 μm) were acquired on a vibrating microtome containing the mesencephalon for immunocytochemistry. TH (Chemicon International Inc., Temecula, California, USA; 1: 1000) immunostaining with the ABC detection method (Vector Lab MI, USA) was performed for light microscope analysis. The analysis was carried out using a computer-assisted system (Image-Pro Plus; Media Cybernetics, Del Mar, California, USA) connected by a CCD camera to an Optiphot 2 Microscope (Nikon, Mexico). The number of TH+ neurons was counted in 1500 mm2 from each animal's seven SNc sections per hemisphere [25–28, 32].

## **3. Statistical analysis**

An unpaired t-test was used to analyze the number of cells. Motor performances were analyzed using repeated-measures ANOVA on mean values of motor activity per certain period, and *post hoc* comparisons were made with Tukey's test. Group differences were considered statistically significant at p < 0.05. All analyses were conducted with GraphPad Prism Software Inc., Version 9 for Mac [25–28].

## **4. Results**

## **4.1 Rotarod performance**

This test estimates motor coordination and balance. Both features are under the dorsal striatum control [33, 34].

First, we explored the deficit degree in motor coordination and balance produced by the unilateral MFB lesion six months after; we found that the fall latency (or permanence on the roll) decreased significantly from 15 rpm (p < 0.05), as seen in **Figure 2**.

#### **Figure 2.**

*Rotarod Permanence time at (5, 10, 15, 20, 25 rpm) of the control, 6-OHDA-lesioned, and Mn-exposed groups after six months. It is observed that the higher the rod speed, the performance in this test was more deficient. Performance in the pre-exposure test was considered 100%. (\* = P < 0.005 6-OHDA-lesion and Mn-exposure versus control group; # = P < 0.005 Mn-exposure versus 6-OHDA-lesion; repeated-measures ANOVA followed by Tukey post hoc test).*

**Figure 2** also shows the Mn mixture-exposed rats' results, observing a progressive decrease in rod permanence directly proportional to the months of exposure. Between the pre-exposure stage vs. three months, an evident reduction is kept in the permanence time at revolutions 20 and 25, decreasing by 46% and 8%, respectively. However, after six months, the decrease in the rode permanence time was evident in the five evaluated revolutions (5, 10, 15, 20, and 25 rpm) due to the significant falls between 70 to 90%. **Figure 2** shows the performance in the test after six months of experimental performances. The pre-groups are not shown because they were considered 100%.

#### **4.2 Open-field test**

In addition to assessing gross motor deficit, we decided to explore the effect of the lesion and Mn-inhalation on the animals' overall spontaneous motor behavior. Openfield testing after the 6-OHDA lesion revealed that voluntary movement and exploration decreased significantly to 44.87 ± 29.50% on average (**Figure 3**). As seen in the representative traces of the route (**Figure 4A**), the animal in its intact condition moved profusely through the open field, exploring the entire perimeter of the arena and sometimes the center, with few periods of inactivity. After three months of the unilateral MFB 6-OHDA lesion, the same animal made a much smaller movement (which is reflected in the low density of lines in the x-y axes), almost did not cross the center of the arena, and presented prolonged periods in which it stopped staying in expectation, or simply immobile in the corners (akinesia), this is observed in the route as a space between the movements on the t-axis (see the middle trace of **Figure 4A**). The Mn-exposed group also decreased the exploratory activity compared to the pre-exposure stage (**Figure 5**). The animals, before Mn inhalation, traveled the average maximum distance of 5875 cm in 20 min (this value was taken as 100%); after three months of exposure, a significant decrease was observed; on average, each animal traveled a distance of 3250 cm which is equivalent to

*Behavioral and Cytological Differences between Two Parkinson's Disease Experimental Models DOI: http://dx.doi.org/10.5772/intechopen.108268*

#### **Figure 3.**

*The 6-OHDA lesion altered the ambulatory performance assessed by the distance traveled, the walking distance, and the rearing frequency, inducing bradykinesia and freezing in the first ten minutes. (One-way repeatedmeasures ANOVA) but it did not significantly affect bradykinesia. \*P < 0.001 compared with control. The data are given as the mean ± SEM).*

#### **Figure 4.**

*(A) The representative traces are shown in a three-dimensional form of a rat's path (x-y in time) in the two stages of the protocol after the 6-OHDA lesion. The number of lines is proportional to the total distance traveled. (B) Images showing the path of a rat in the pre-and after Mn exposure stages. It is evident that after Mn inhalation, and presumably by the loss of dopaminergic innervation, the animals did so attached to the walls when they wandered.*

**Figure 5.**

*MnCl2/Mn(OAc)3 inhalation decreased ambulatory activity measured by distance traveled, rearing frequency, and walking distance, and induced significant bradykinesia and freezing during the first ten minutes in the open field (one-way repeated-measures ANOVA). \* P < 0.001 compared with control (the data are given as the mean ± SEM).*

45% decrease (**Figure 5**); however, at six months the decline was more evident, corresponding to 66% covering a distance of 1985.83 cm in 20 min (**Figures 4B** and **5**).

As can be seen, the inhalation of Mn, by producing bilateral dopaminergic damage, accentuates the alterations in a time-dependent manner (in both rotarod and open field tests) more clearly compared to the unilateral 6-OHDA-lesioned group. Moreover, the qualitative evaluation showed that Mn-exposed animals exhibit hindlimb weakness, poverty of spontaneous movement (akinesia), slowness of movement (bradykinesia), action tremor, and postural instability.

#### **4.3 Tyrosine hydroxylase immunocytochemistry**

TH+ neurons counting found that in the 6-OHDA unilaterally lesioned rats, SNc had 95.4% of dopaminergic neurons lost on the ipsilateral side than the contralateral (**Figures 6** and **7**). The number of TH<sup>+</sup> neurons in the control group, both contra and ipsilateral SNc, remained unaffected (94 ± 1.9 and 93 ± 1.7, respectively) (**Figure 6**). In contrast, we found a substantial loss of TH-positive neurons in the SNc of 6-OHDA lesioned animals in both contralateral (73 ± 1.9) and ipsilateral (5 ± 1.6) SNc compared to controls as shown in **Figures 6** and **7**.

Also, after six months of MnCl2/Mn(OAc)3 inhalation, a significant loss of the TH<sup>+</sup> neurons in the SNc was observed (70.58%) compared to the control group (**Figures 6** and **7**).

*Behavioral and Cytological Differences between Two Parkinson's Disease Experimental Models DOI: http://dx.doi.org/10.5772/intechopen.108268*

**Figure 6.**

*SNc TH+ cell number. The data are presented as the mean ± SEM. A statistically significant decrease in TH-immunoreactive cells was detected in MnCl2/Mn(OAc)3-exposed group and both 6-OHDA-lesioned contralateral and ipsilateral SNc; being more drastic in the 6-OHDA ipsilateral SNc (\* = P < 0.05 versus control group; ANOVA test).*

#### **Figure 7.**

*Illustrative TH<sup>+</sup> from coronal sections containing the SNc of control, 6-OHDA, and MnCl2/Mn(OAc)3-exposed rats; it is evident the loss of dopaminergic neurons in both experimental groups is more drastic in the 6-OHDA ipsilateral SNc (magnification 10×).*

**Figures 6** and **7** clearly show the laterality of the neural loss in the unilaterally 6-OHDA-lesioned animals, unlike the rats that inhaled Mn, who presented significant bilateral cell loss.

## **5. Discussion**

A reliable PD experimental model must gradually mimic the physiological and behavioral symptoms such as bradykinesia, akinesia, tremor, and muscle rigidity, allowing intervention in the early stages of the disease [5, 35, 36].

There are currently several experimental models that reproduce PD. These models were aimed to induce nigrostriatal dopaminergic depletion. Selective neurotoxins such as 6-OHDA, MPTP, paraquat, or rotenone are generally used [4, 7, 9]. These models induce neuronal death by inhibiting mitochondrial function and producing ROS. Still, none fully reproduce the symptoms and pathology seen in PD patients, in part because the activity of the neurotoxins is acute, fast, unilateral, and nonprogressive, and the response to these neurotoxins is different between species [4].

Our results evidence that the alterations between the two models are similar; however, the animals exposed to the Mn mixture had time-dependent behavioral alterations, while the animals lesioned with 6-OHDA presented alterations almost immediately, the neuronal loss is massive and mainly unilateral, so it is complicated to prove a treatment with 5% remaining dopaminergic neurons.

#### **5.1 Rotarod performance**

The rotarod is commonly used to behaviorally assess the degree of dopaminergic depletion (maximum or partial) in PD models [37]; this test also assesses akinesia and postural instability symptoms.

The exact mechanism underlying this test is the failure of the dopamine-depleted rats to remain on the rod; these deficits become increasingly apparent as the speed of rotation increases and the rats are obligated to move faster. There is also evidence of loss in the ability to apply force with the affected extremities; therefore, there is fatigue [38], and they tend to fall (fall latency). It has recently been shown that PD patients present instability and movement inaccuracy which becomes more prominent when they are asked to move faster [39]. The motor alterations became more evident at 20 and 25 rpm; after six months of dopamine depletion, motor coordination decreased significantly in the five evaluated revolutions. The dopaminedepleted animals tended to remain static before starting the test, so when the rotarod was turned on, it was easy for them to lose their balance and fall or not coordinate their steps with the movement of the rod when the revolutions increased. Similar results have also been reported by Rozas et al. [37] using the rotarod test in mice that received injections of MPTP, the animals showed a reduction in the time spent on the rod, related to the SNc dopamine loss. Subsequently, Razgado-Hernandez et al. [30] report the association between the degree of motor coordination deficit and the balance produced by 6-OHDA unilateral lesion in the MFB, where there is an 89.4% loss of TH+ neurons in the lesioned SNc.

Our data demonstrate that the Mn-exposed rats had more trouble staying on the rod since the dopaminergic denervation is bilateral, just like the PD patients.

*Behavioral and Cytological Differences between Two Parkinson's Disease Experimental Models DOI: http://dx.doi.org/10.5772/intechopen.108268*

### **5.2 Open field performance**

The open field is a reliable test in rodents to assess motor activity as it measures (spontaneous motor behavior) that is an analog in PD patients when they present hypokinesia (decreased ambulation) and bradykinesia (reduced speed of movement).

Among the cardinal PD symptoms are akinesia and postural instability. Akinesia can be the most disabling symptom (along with tremors). It can be subdivided into different components such as delayed initiation of movement (prolonged reaction time (bradykinesia), inability to reach an object with continuous movement, rapid fatigue with repetitive motions, and balance disorders [35, 39]. The locomotion decrease is indicative of an altered state of motor behavior typical of parkinsonism, and the reduction obtained is similar to that reported by [40] for a unilateral 6-OHDA MFB lesion. In the 6-OHDA-lesioned rats, the walking distance appears unaffected, so there is no bradykinesia; we found some akinesia probably associated with a lack of motivation to move and explore the environment.

In contrast, regarding the animals exposed to Mn, before the inhalation, the rats maintained spontaneous exploration activity; however, when Mn-exposed, the spontaneous activity significantly decreased; this decrease was progressive; after three months, the decline was 45%, but after six months it was 76%, this response indicates that the model reproduces the symptoms of hypokinesia (decreased ambulation) which causes them to walk less distance and bradykinesia since their walking speed was altered, alterations reported previously by our group [41]. We also observed tremors, a symptom the 6-OHDA-lesioned rats did not present. Qualitative inspection indicated that Mn-exposed rats display hind-limb weakness, poverty of spontaneous movement (akinesia), slowness of movement (bradykinesia), action tremor, postural instability, and freezing behavior. About these alterations, Harischandra et al. [15] stated that mice exposed subchronically to Mn by intragastric gavage displayed hypoactivity; this alteration was associated with 50% striatal dopamine depletion; Eriksson et al. [42] found that after five months of Mn exposure the animals developed unsteady gait, subsequently action tremor and were hypoactive. The animals lost strength in both upper and lower extremities, and their paw movements were clumsy [42].

It is well known that rats with both MFB 6-OHDA lesions have postural instability and little ability to preserve equilibrium after tasks with destabilizing forces. Similarly, spontaneous movements are significantly altered [43]; this has not been reported after the unilateral 6-OHDA lesion.

Parkinsonian-like tremors have been scarce in unilaterally 6-OHDA-lesioned rats [44, 45]; nevertheless, Schallert et al. [46] have reported infrequent tremors in the paw and the wrist of rats with almost complete dopamine denervation (either bilateral or unilateral). This tremor is observed when the paw is placed off the floor in a non-weight-bearing posture [46]. It is also known that bilaterally 6-OHDA- lesioned rats show most of the PD motor symptoms. However, 6-OHDA bilateral lesion is not a typical PD model since the lesioned animals need intensive care since they present adipsia and aphagia and die a few days after the lesion [47]. Therefore, the MFB unilateral 6-OHDA lesion is the most commonly used PD model, even though it does not replicate all the PD symptoms and pathological characteristics. Likewise, the acute kind of the experimental models contrasts with the dopaminergic nigral neuron's progressive degeneration in PD [41].

### **5.3 Tyrosine hydroxylase immunocytochemistry**

We observed a severe decrease (95%) of TH+ cells after the unilateral 6-OHDA lesion in the ipsilateral SNc. The MFB 6-OHDA unilateral lesion produces a severe SNc degeneration, mainly in the ipsilateral side, within the first hours after the lesion, corroborated by apomorphine-induced circling behavior [48] and TH+ cell count (see **Figures 6** and **7**). Our results concur with Surmeier [49], who reported that PD patients have up to 95% of dopaminergic neuron reduction in the advanced stages of the disease. Similarly, it has been confirmed that the MFB unilateral lesion decreases 95–98% of the SNc ipsilateral number of TH+ neurons [50, 51]. We also found a significant cell loss in the contralateral SNc, as reported previously by our group [52, 53]; however, the cell loss in the contralateral SNc is not enough to simulate PD symptoms. Similarly, it has been described that the reserpine rat PD model is known to induce a substantial dopamine depletion with a rapid development of striatal dopaminergic receptors supersensitivity (within 12–24 h after reserpine) [54]. Other authors have shown that most severely lesioned parkinsonian primates subjected to chronic MPTP regimens present 70–80% nigral TH+ cell loss and >95% striatal dopamine depletion [55].

According to previous reports [25–28, 41], we found a substantial loss of TH+ neurons, as shown in **Figures 6** and **7**, displaying a very similar pattern to that reported in the middle to advanced stages of the PD; it has been described neurochemical variations in humans and animals Mn-intoxicated involving the decrease in dopamine concentration and TH+ immunoreactivity in the SNc and striatum [13, 15, 16, 56–59]. Hence, it has been supposed that Mn interacts with catechols specific to dopaminergic neurons to diminish them promptly, causing these cells to no longer be viable [60, 61]. However, there has been controversy about Mn-inducing SNc dopaminergic damage [18, 20, 22, 24, 62–65]. According to these authors, Mn exposure leads mainly to Globus Pallidus and striatal alterations without affecting the SNc dopaminergic neurons. Our results are probably because we exposed the animals to a mixture of divalent and trivalent Mn. Divalent Mn pro-oxidant activity seems to depend on trivalent Mn trace amounts, which may enable Mn2+ small portion to oxidize to Mn3+. This relationship between both Mn compounds results in a continuous redox cycle [66]. It seems that divalent Mn does not have oxidative effects; nevertheless, the transition of Mn2+ to Mn3+ accelerates its oxidant capability, which might consequence in the production of reactive oxygen species, cell membrane damage, and lipid peroxidation [61], which, in turn, could affect catecholamines [67, 68]; therefore, the inherent transformation of divalent Mn to trivalent Mn and the existence of more trivalent Mn might provoke mitochondrial dysfunction and more reactive oxygen species [68, 69] manifested as the evident motor alterations and the dopaminergic neuronal death, reported here.

Numerous reasons have been suggested to explain the SNc dopaminergic cell's susceptibility to Mn. First, the lack of cellular antioxidant defenses, and second, the mitochondrial oxidative energy metabolism disruption [69]. This has led to the assumption that extreme brain Mn levels provoke oxidative stress leading to neurodegeneration [66]. However, the main reason for the specificity of Mn for the SNc dopaminergic neurons is related to the dopamine transporter (DAT); it has been reported that Mn arrives in the neurons via DAT [70–73]; DAT is related to the MPTP [74], and 6-OHDA neurotoxicity [75], where SNc is more vulnerable than other dopaminergic areas, such as the ventral tegmental area (VTA). It seems that the VTA and SNc dopaminergic cells exhibit topography, biochemistry, and susceptibility to pathological processes differences [76]; the middle and medial SNc express higher levels of DAT than the VTA [74, 77]; thus, Mn possibly get SNc dopaminergic cells through the greater amounts of DAT reported on

*Behavioral and Cytological Differences between Two Parkinson's Disease Experimental Models DOI: http://dx.doi.org/10.5772/intechopen.108268*

those neurons. Moreover, in PD, the most vulnerable neurons are the SNc dopaminergic ones and not those of the VTA [76, 77].

Currently, available PD experimental models have contributed significantly to our knowledge of the disease's neurotransmitter changes, potential neuroprotective therapeutics, and pathophysiology [6, 7]. However, so far, we do not have the most suitable model. MPTP experimental model is the best available one for some reasons, and it has been essential for testing neurorestorative and neuroprotective approaches [4]. Nevertheless, the MPTP model disadvantages are acute damage to the dopaminergic system and infrequent generation of inclusion bodies, different susceptibility among species, and recovery after exposure ceased [78]. Both MPTP and 6-OHDA models differ from the slowly progressive pathology of human PD [4]. In addition, PD genetic models seem to simulate some features of the disease without extensive SNc neuronal loss [79]. Transgenic mice overexpressing wild-type and mutant alfasynuclein demonstrate motor deficits without loss of dopaminergic neurons [4, 80].

The substantial reduction (72 %) in the number of SNc dopaminergic cells after divalent/trivalent Mn inhalation observed here establishes an evident reduction of this catecholamine content. Therefore, we suppose the motor PD symptoms are due to dopaminergic denervation since L-DOPA-treated animals almost entirely improved their motor performance [27, 28].

## **6. Conclusion**

For some years, PD has shown a significant increase in its prevalence, which is why it has been the focus of multiple investigations worldwide. All these investigations strive to explain the pathophysiological mechanisms of the disease and the best therapeutic alternatives. To accomplish this, we have resorted to the design and use of various animal models, representing an opportunity to study aspects of the disease from different perspectives.

When choosing an animal PD model, the stated objective, scope of the research, and the similarities or discrepancies between the anatomy, physiology, and behavior of humans and animals should be considered. In this chapter, we compared the motor alterations of the model due to unilateral 6-OHDA lesions and inhalation of the MnCl2/Mn(OAc)3 mixture.

Our results showed that 6-OHDA unilateral lesion produces acute loss of dopaminergic neurons. These animals did not appear to present bradykinesia and tremor, both clinical aspects that are considered cardinal in PD patients. Unlike 6-OHDA or MPTP PD models, where all symptoms happen in a few days or weeks, or even hours, while in PD patients progress over decades [81]; our Mn mixture-inhaled model seems to be adequate because the symptoms and cell death are bilateral and, and the variances between species are insignificant [25–28]. According to Schober [78], an ideal PD model must develop the following characteristics: (1) an average number of SNc dopaminergic neurons at birth followed by the gradual and selective loss of these cells beginning in adulthood; (2) easily detectable and quantifiable motor deficits; (3) Lewy bodies; (4) the model, ideally must have a reasonably short time course to simulate the PD pathogenesis (about 3–6 months), which would grant a prompt assessment of therapeutic schemes [78]. Therefore, we replicate at least three of those features with our model [25–28]. However, additional studies are required to clarify whether Mn-mixture inhalation produces Lewy bodies, reduces striatal dopamine concentrations, and determine if the animals recover after the inhalation.

Finally, our data and the findings of the Mn-model apport crucial knowledge concerning a better understanding of the mechanisms related to the PD nigrostriatal degeneration since it adequately simulates the neurochemical, neuroanatomical, and some behavioral characteristics of PD.

## **Acknowledgements**

This work was supported by COMECyT FICDTEM-2021-066 and PAPIIT-DGAPA IN216821 grants. We are very grateful to Patricia Aley-Medina, Jesús Espinosa-Villanueva and Veronica Rodriguez Mata for their excellent photographic and technical assistance.

## **Conflict of interest**

Authors have declared that no competing interests exist.

## **Author details**

Maria Rosa Avila-Costa1 \*, José Luis Ordoñez-Librado1 , Ana Luisa Gutierréz-Valdez1 , Javier Sanchez-Betancourt1 , Ma Teresa Ibarra-Gutiérrez2 , Patricia E. Reyna-Velázquez3 , Verónica Anaya-Martínez3,4, Cesar Alfonso Garcia Caballero1 , Enrique Montiel-Flores1 , Claudia Dorado-Martínez1 , Leonardo Reynoso-Erazo5 , Vianey Rodríguez-Lara6 and Rocío Tron-Alvarez5

1 Facultad de Estudios Superiores Iztacala, Neuromorphology Lab, UNAM, Tlalnepantla, Mexico

2 Molecular and Cellular Neurobiology Lab, National Institute of Neurology and Neurosurgery, Mexico

3 Department of Physiology, Biophysics and Neurosciences, Cinvestav, Mexico City, Mexico

4 Faculty of Health Sciences, Center for Research in Health Sciences, Anahuac University, Huixquilucan, Mexico

5 Facultad de Estudios Superiores Iztacala, Health Education Project, UNAM, Tlalnepantla, Mexico

6 Facultad de Medicina, Department of Cell Biology, Nacional University of Mexico (UNAM), Mexico City, Mexico

\*Address all correspondence to: nigraizo@unam.mx

© 2022 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

## **References**

[1] Naskar A, Manivasagam T, Chakraborty J, Singh R, Thomas B, Dhanasekaran M, et al. Melatonin synergizes with low doses of L-DOPA to improve dendritic spine density in the mouse striatum in experimental Parkinsonism. Journal of Pineal Research. 2013;**55**:304-301

[2] Rangel-Barajas C, Coronel I, Florán B. Dopamine receptors and neurodegeneration. Aging and Disease. 2015;**6**:349-368

[3] Michel PP, Hirsch EC, Hunot S. Understanding dopaminergic cell death pathways in parkinson disease. Neuron. 2016;**90**:675-691

[4] Betarbet R, Sherer TB, Greenamyre JT. Animal models of Parkinson's disease. BioEssays. 2002;**24**:308-318

[5] Gubellini P, Kachidian P. Animal models of Parkinson's disease: An updated overview. Revue Neurologique (Paris). 2015;**171**:750-761

[6] Emborg ME. Evaluation of animal models of Parkinson's disease for neuroprotective strategies. Journal of Neuroscience Methods. 2004;**139**:121-143

[7] Bove J, Prou D, Perier C, Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRx. 2005;**2**:484-494

[8] Greenamyre JT, Betarbet R, Sherer TB. The rotenone model of Parkinson's disease: Genes, environment, and mitochondria. Parkinsonism & Related Disorders. 2003;**9**(Suppl. 2):S59-S64

[9] Konnova EA, Swanberg M. Animal models of Parkinson's disease. In: Stoker TB, Greenland JC, editors. Parkinson's Disease: Pathogenesis and

Clinical Aspects. Brisbane (AU): Codon Publications; 2018

[10] von Bohlen und Halbach O, Schober A, Krieglstein K. Genes, proteins, and neurotoxins involved in Parkinson's disease. Progress in Neurobiology. 2004;**73**:151-177

[11] Cook DG, Fahn S, Brait KA. Chronic manganese intoxication. Archives of Neurology. 1974;**30**:59-64

[12] Calne DB, Chu NS, Huang CC, Lu CS, Olanow W. Manganism and idiopathic parkinsonism: Similarities and differences. Neurology. 1994;**44**:1583-1586

[13] Pal PK, Samii A, Calne DB. Manganese neurotoxicity: A review of clinical features, imaging and pathology. Neurotoxicology. 1999;**20**:227-238

[14] Kwakye GF, Paoliello MM, Mukhopadhyay S, Bowman AB, Aschner M. Manganese-induced Parkinsonism and Parkinson's disease: Shared and distinguishable features. International Journal of Environmental Research and Public Health. 2015;**12**:7519-7540

[15] Harischandra DS, Ghaisas S, Zenitsky G, et al. Manganese-induced neurotoxicity: New insights into the triad of protein misfolding, mitochondrial impairment, and neuroinflammation. Frontiers in Neuroscience. 2019;**13**:654

[16] Guilarte TR, Gonzales KK. Manganese-induced Parkinsonism is not idiopathic Parkinson's disease: Environmental and genetic evidence. Toxicological Sciences. 2015;**146**:204-212

[17] Kulshreshtha D, Ganguly J, Jog M. Manganese and movement disorders:

*Behavioral and Cytological Differences between Two Parkinson's Disease Experimental Models DOI: http://dx.doi.org/10.5772/intechopen.108268*

A review. The Journal of Movement Disorders. 2021;**14**:93-102

[18] Kissani N, Naji Y, Mebrouk Y, Chraa M, Ghanima A. Parkinsonism and chronic manganese exposure: Pilot study with clinical, environmental and experimental evidence. Clinical Parkinsonism & Related Disorders. 2020;**3**:100057

[19] Lee EY, Flynn MR, Du G, et al. Nigral MRI features of asymptomatic welders. Parkinsonism & Related Disorders. 2021;**85**:37-43

[20] Calabresi P, Ammassari-Teule M, Gubellini P, Sancesario G, Morello M, Centonze D, et al. A synaptic mechanism underlying the behavioral abnormalities induced by manganese intoxication. Neurobiology of Disease. 2001;**8**:419-432

[21] Salari M, Etemadifar M, Dargahi L, Valian N, Rezaee M. Manganese-induced parkinsonism responsive to intranasal insulin: A case report. Clinical Case Reports. 2022;**10**:e05562

[22] Olanow CW. Manganese-induced parkinsonism and Parkinson's disease. Annals of the New York Academy of Sciences. 2004;**1012**:209-223

[23] Lin M, Colon-Perez LM, Sambo DO, et al. Mechanism of manganese dysregulation of dopamine neuronal activity. The Journal of Neuroscience. 2020;**40**:5871-5891

[24] Perl DP, Olanow CW. The neuropathology of manganeseinduced parkinsonism. Journal of Neuropathology and Experimental Neurology. 2007;**66**:675-682

[25] Ordonez-Librado JL, Anaya-Martinez V, Gutierrez-Valdez AL, Colin-Barenque L, Montiel-Flores E, Avila-Costa MR. Manganese inhalation as a Parkinson disease model. Parkinson's Disease. 2010;**2011**:612989

[26] Ordonez-Librado JL, Gutierrez-Valdez AL, Colin-Barenque L, Anaya-Martinez V, Diaz-Bech P, Avila-Costa MR. Inhalation of divalent and trivalent manganese mixture induces a Parkinson's disease model: Immunocytochemical and behavioral evidences. Neuroscience. 2008;**155**:7-16

[27] Sanchez-Betancourt J, Anaya-Martinez V, Gutierrez-Valdez AL, Ordonez-Librado JL, Montiel-Flores E, Espinosa-Villanueva J, et al. Manganese mixture inhalation is a reliable Parkinson disease model in rats. Neurotoxicology. 2012;**33**:1346-1355

[28] Ordonez-Librado JL, Anaya-Martinez V, Gutierrez-Valdez AL, Montiel-Flores E, Corona DR, Martinez-Fong D, et al. L-DOPA treatment reverses the motor alterations induced by manganese exposure as a Parkinson disease experimental model. Neuroscience Letters. 2010;**47**:79-82

[29] Ungerstedt U. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. European Journal of Pharmacology. 1968;**5**:107

[30] Razgado-Hernandez LF, Espadas-Alvarez AJ, Reyna-Velazquez P, Sierra-Sanchez A, Anaya-Martínez V, Jimenez-Estrada I, et al. The transfection of BDNF to dopamine neurons potentiates the effect of dopamine D3 receptor agonist recovering the striatal innervation, dendritic spines and motor behavior in an aged rat model of Parkinson's disease. PLoS One. 2015;**10**:e0117391

[31] Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. London: Academic Press, Elsevier; 2005

[32] Avila-Costa MR, Montiel Flores E, Colin-Barenque L, Ordoñez JL, Gutiérrez AL, Niño-Cabrera HG, et al. Nigrostriatal modifications after vanadium inhalation: An immunocytochemical and cytological approach. Neurochemical Research. 2004;**29**:1365-1369

[33] Robbe D. To move or to sense? Incorporating somatosensory representation into striatal functions. Current Opinion in Neurobiology. 2018;**52**:123-130

[34] Durieux PF, Schiffmann SN, de Kerchove d'Exaerde A. Differential regulation of motor control and response to dopaminergic drugs by D1R and D2R neurons in distinct dorsal striatum subregions. The EMBO Journal. 2012;**31**:640-653

[35] Raza C, Anjum R, Shakeel NUA. Parkinson's disease: Mechanisms, translational models and management strategies. Life Sciences. 2019;**226**:77-90

[36] Zeng XS, Geng WS, Jia JJ. Neurotoxin-induced animal models of parkinson disease: Pathogenic mechanism and assessment. ASN Neuro. 2018;**10**:1759091418777438

[37] Rozas G, López-Martín E, Guerra MJ, Labandeira-García JL. The overall rod performance test in the MPTP-treatedmouse model of Parkinsonism. Journal of Neuroscience Methods. 1998;**83**:165-175

[38] Boix J, Padel T, Paul G. A partial lesion model of Parkinson's disease in mice--characterization of a 6-OHDAinduced medial forebrain bundle lesion. Behavioural Brain Research. 2015;**284**:196-206

[39] Freed WJ, Fernandez L, Huys R, Issartel J, Azulay JP, Eusebio A. Movement speed-accuracy trade-off in Parkinson's disease. Frontiers in Neurology. 2018;**9**:897

[40] Eskow Jaunarajs KL, George JA, Bishop C. L-DOPA-induced dysregulation of extrastriatal dopamine and serotonin and affective symptoms in a bilateral rat model of Parkinson's disease. Neuroscience. 2012;**218**:243-256

[41] Ordoñez-Librado JL, Gutierrez-Valdez AL, Montiel-Flores E, Rodríguez-Lara V, Reynoso-Erazo L, Tron-Alvarez R, Avila-Costa M. R. Divalent and trivalent manganese mixture inhalation as a Parkinson disease model. Challenges in Disease and Health Research Vol. 6. BP International; 2021. 102-125.

[42] Eriksson H, Mägiste K, Plantin L-O, Fonnum F, Hedström K-G, Theodorsson-Norheim E, et al. Effects of manganese oxide on monkeys as revealed by a combined neurochemical, histological and neurophysiological evaluation. Archives of Toxicology. 1987;**61**:46-52

[43] Wang Z, Flores I, Donahue EK, et al. Cognitive flexibility deficits in rats with dorsomedial striatal 6-hydroxydopamine lesions tested using a three-choice serial reaction time task with reversal learning. Neuroreport. 2020;**31**:1055-1064

[44] Lindner MD, Cain CK, Plone MA, Frydel BR, Blaney TJ, Emerich DF, et al. Incomplete nigrostriatal dopaminergic cell loss and partial reductions in striatal dopamine produce akinesia, rigidity, tremor and cognitive deficits in middleaged rats. Behavioural Brain Research. 1999;**102**:1-16

[45] Cenci MA, Whishaw IQ, Schallert T. Animal models of neurological deficits: How relevant is the rat? Nature Reviews. Neuroscience. 2002;**3**:574-579

*Behavioral and Cytological Differences between Two Parkinson's Disease Experimental Models DOI: http://dx.doi.org/10.5772/intechopen.108268*

[46] Schallert T, Petrie BF, Whishaw IQ. Neonatal dopamine depletion: Spared and unspared sensorimotor and attentional disorders and effects of further depletion in adulthood. Psychobiology. 1989:386-396

[47] Ungerstedt U. Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiologica Scandinavica. Supplementum. 1971;**367**:95-122

[48] Ungerstedt U, Arbuthnott GW. Quantitative recording of rotational behavior in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain Research. 1970;**24**:485-493

[49] Surmeier DJ. Determinants of dopaminergic neuron loss in Parkinson's disease. The FEBS Journal. 2018;**285**:3657-3668

[50] Allbutt HN, Henderson JM. Use of the narrow beam test in the rat, 6-hydroxydopamine model of Parkinson's disease. Journal of Neuroscience Methods. 2007;**159**:195-202

[51] Dowd E, Dunnett SB. Comparison of 6-hydroxydopamine-induced medial forebrain bundle and nigrostriatal terminal lesions in a lateralised nosepoking task in rats. Behavioural Brain Research. 2005;**159**:153-161

[52] Avila-Costa M, Gutierrez-Valdez A, Ordonez-Librado J, Martinez V, Colin-Barenque L, Espinosa-Villanueva J, et al. Time course changes of the striatum neuropil after unilateral dopamine depletion and the usefulness of the contralateral striatum as a control structure. Neurological Research. 2008;**30**:1068-1074

[53] Anaya-Martinez V, Gutierrez-Valdez AL, Ordonez-Librado JL,

Montiel-Flores E, Sanchez-Betancourt J, Sanchez Vazquez del Mercado C, et al. The presence of perforated synapses in the striatum after dopamine depletion, is this a sign of maladaptive brain plasticity? Microscopy (Oxf). 2014;**63**:427-435

[54] Trugman JM, James CL. Rapid development of dopaminergic supersensitivity in reserpine-treated rats demonstrated with 14C-2-deoxyglucose autoradiography. The Journal of Neuroscience. 1992;**12**:2875-2879

[55] Di Monte DA, McCormack A, Petzinger G, Janson AM, Quik M, Langston WJ. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model. Movement Disorders. 2000;**15**:459-466

[56] Ellingsen DG, Shvartsman G, Bast-Pettersen R, Chashchin M, Thomassen Y, Chashchin V. Neurobehavioral performance of patients diagnosed with manganism and idiopathic Parkinson disease. International Archives of Occupational and Environmental Health. 2019;**92**:383-394

[57] Thiruchelvam M, Richfield EK, Baggs RB, Tank AW, Cory-Slechta DA. The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: Implications for Parkinson's disease. The Journal of Neuroscience. 2000;**20**:9207-9214

[58] Sistrunk SC, Ross MK, Filipov NM. Direct effects of manganese compounds on dopamine and its metabolite Dopac: An in vitro study. Environmental Toxicology and Pharmacology. 2007;**23**:286-296

[59] Sriram K, Lin GX, Jefferson AM, Roberts JR, Chapman RS, Chen BT, et al. Dopaminergic neurotoxicity following pulmonary exposure to manganesecontaining welding fumes. Archives of Toxicology. 2010;**84**:521-540

[60] Peres TV, Schettinger MR, Chen P, et al. Manganese-induced neurotoxicity: A review of its behavioral consequences and neuroprotective strategies. BMC Pharmacology and Toxicology. 2016;**17**:57

[61] Archibald FS, Tyree C. Manganese poisoning and the attack of trivalent manganese upon catecholamines. Archives of Biochemistry and Biophysics. 1987;**256**:638-650

[62] Aschner M, Erikson KM, Herrero Hernandez E, Tjalkens R. Manganese and its role in Parkinson's disease: From transport to neuropathology. Neuromolecular Medicine. 2009;**11**:252-266

[63] Erikson KM, Dobson AW, Dorman DC, Aschner M. Manganese exposure and induced oxidative stress in the rat brain. Science of the Total Environment. 2004;**334-335**:409-416

[64] Struve MF, McManus BE, Wong BA, Dorman DC. Basal ganglia neurotransmitter concentrations in rhesus monkeys following subchronic manganese sulfate inhalation. American Journal of Industrial Medicine. 2007;**50**:772-778

[65] Gwiazda RH, Lee D, Sheridan J, Smith DR. Low cumulative manganese exposure affects striatal GABA but not dopamine. Neurotoxicology. 2002;**23**:69-76

[66] HaMai D, Bondy SC. Oxidative basis of manganese neurotoxicity. Annals of the New York Academy of Sciences. 2004;**1012**:129-141

[67] Ali SF, Duhart HM, Newport GD, Lipe GW, Slikker W. Manganese-induced reactive oxygen species: Comparison between Mn+2 and Mn+3. Neurodegeneration. 1995;**4**:329-334

[68] Díaz-Véliz G, Mora S, Gómez P, Dossi MT, Montiel J, Arriagada C, et al. Behavioral effects of manganese injected in the rat substantia nigra are potentiated by dicumarol, a DT-diaphorase inhibitor. Pharmacology, Biochemistry, and Behavior. 2004;**77**:245-251

[69] Morello M, Canini A, Mattioli P, Sorge RP, Alimonti A, Bocca B, et al. Sub-cellular localization of manganese in the basal ganglia of normal and manganese-treated rats: An electron spectroscopy imaging and electron energy-loss spectroscopy study. Neurotoxicology. 2008;**29**:60-72

[70] Gunter TE, Gavin CE, Aschner M, Gunter KK. Speciation of manganese in cells and mitochondria: A search for the proximal cause of manganese neurotoxicity. Neurotoxicology. 2006;**27**:765-776

[71] Ingersoll RT, Montgomery EB, Aposhian HV. Central nervous system toxicity of manganese. II: Cocaine or reserpine inhibit manganese concentration in the rat brain. Neurotoxicology. 1999;**20**:467-476

[72] Erikson KM, John CE, Jones SR, Aschner M. Manganese accumulation in striatum of mice exposed to toxic doses is dependent upon a functional dopamine transporter. Environmental Toxicology and Pharmacology. 2005;**20**:390-394

[73] Anderson JG, Cooney PT, Erikson KM. Inhibition of DAT function attenuates manganese accumulation in the globus pallidus. Environmental Toxicology and Pharmacology. 2007;**23**:179-184

[74] Masoud ST, Vecchio LM, Bergeron Y, et al. Increased expression *Behavioral and Cytological Differences between Two Parkinson's Disease Experimental Models DOI: http://dx.doi.org/10.5772/intechopen.108268*

of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits. Neurobiology of Disease. 2015;**74**:66-75

[75] Lehmensiek V, Tan EM, Liebau S, et al. Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson's disease. Neurochemistry International. 2006;**48**:329-340

[76] Brichta L, Greengard P. Molecular determinants of selective dopaminergic vulnerability in Parkinson's disease: An update. Frontiers in Neuroanatomy. 2014;**8**:152

[77] Bhaskar S, Gowda J, Prasanna J, Kumar A. Does altering proteasomal activity and trafficking reduce the arborization mediated specific vulnerability of SNpc dopaminergic neurons of Parkinson's disease? Medical Hypotheses. 2020;**143**:110062

[78] Schober A. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell and Tissue Research. 2004;**318**:215-224

[79] Goldberg MS, Fleming SM, Palacino JJ, Cepeda C, Lam HA, Bhatnagar A, et al. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. The Journal of Biological Chemistry. 2003;**278**:43628-43635

[80] Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VMY. Neuronal α-Synucleinopathy with severe movement disorder in mice expressing A53T Human α-Synuclein. Neuron. 2002;**34**:521-533

[81] Bloem BR, Okun MS, Klein C. Parkinson's disease. Lancet. 2021;**397**: 2284-2303

**Chapter 4**

## Early Diagnosis of Parkinson' s Disease: Utility of Animal Models

*Neha S, Mohammad Ahmad, Baby Kumari, MD. Zainul Ali and Pankaj Singh Dholaniya*

## **Abstract**

The effectiveness of the treatment strategies for Parkinson's disease (PD) is highly dependent on the time of therapeutic intervention. This makes early diagnosis of PD an essential factor for its treatment; however, the complexities of the symptoms make it difficult to diagnose at an early stage. Moreover, by the time the symptoms start to appear, the disease has already been propagated in the patients. Even for the researchers, it is difficult to understand the important early diagnostic biomarkers due to the unavailability of the patients at the early stage, that is, before the manifestation of visible symptoms. The solution to this problem appears to develop animal models and monitor them from the early days to discover the diagnostic biomarkers. In this chapter, we shall discuss the use of animal models in the research intended to discover early diagnostic biomarkers for PD and why it is important to use animal models.

**Keywords:** alpha-synuclein, animal models, biomarkers, dopaminergic neurons, early diagnosis, neurodegeneration, Parkinson's disease, prodromal stage, rotenone, substantia nigra, transgenic models

## **1. Introduction**

The number of Parkinson's disease (PD) cases per year is rising worldwide. In the coming two decades, it is estimated to outpace Alzheimer's disease in terms of casualties [1]. The economic burden of PD is also very high, as it can be understood by the fact that the US alone spends more than \$50 billion annually on PD [2]. The disease goes unnoticed in the earlier stages as neurons are highly arborized and redundant; therefore, when degeneration of dopaminergic neurons starts, other neurons compensate for this loss. Consequently, motor symptoms appear when nearly half of the dopaminergic neurons have degenerated [2, 3]. PD's effects on the central nervous system are prolonged, and the neuronal damage cannot be reversed, making the disease's symptoms and progression inexorable. By the time PD is diagnosed, individuals have difficulty coordinating their bodies due to tremors, bradykinesia, stiffened limbs or trunk, and poor balance. Also, moving, speaking, swallowing, and other ordinary functions can become problematic as the symptoms progress. Apart from obvious motor-related symptoms, there are a few non-motor symptoms such as behavioral changes, sleep-related disorders, cognitive impairment, constipation etc.

that severely impact the healthy well-being of the individuals. Interestingly, some non-motor symptoms such as hyposmia, REM sleep behavior disorder (RBD), constipation, etc., follow motor symptoms over many years [4–8]. The multifactorial nature of PD makes it difficult for clinical diagnosis as the symptoms and causes are not universal among all patients. Particularly early diagnosis of PD is challenging because the symptoms at an early stage overlap with other diseases and normal aging. There is a need to identify biomarkers that can be helpful in early and accurate diagnosis, which must be aimed to prevent PD progression. In this chapter, we first discuss the different aspects of PD diagnosis, followed by challenges in early diagnosis. We also discuss the existing animal models used in PD research. Later we shall focus on various diagnostic markers and the utility of animal models. We conclude by stating the importance of animal models in PD research intended to discover early diagnostic biomarkers.

## **2. Different aspects of PD diagnosis**

There are different aspects to diagnose PD, such as (1) Non-motor symptom assessment, (2) Brain imaging, and (3) Molecular markers-based diagnosis—e.g., metabolome analysis, miRNA-based analysis, genome sequencing.

### **2.1 Non-motor symptoms assessment**

It has been shown that a few non-motor symptoms appear before the inception of the motor symptoms, e.g., Smell loss or hyposmia is a common phenomenon in PD (75–95%), however, a study reports 25% of the normal population faces smell loss at later stages of life [9–11]. Constipation associated problems have been reported in PD, but only 15–20% of patients suffer from this problem [6, 7]. RBD is often reported in PD patients. It has been reported that 67% of patients with RBD complaints whose nigrostriatal dopaminergic system is damaged, develop PD within 4 years [4, 5]. Although these non-motor symptoms help in PD diagnosis, their accuracy is very low. As these symptoms are not exclusive to PD, there is a need to identify a set of important non-motor symptoms that can accurately predict PD condition.

## **2.2 Brain imaging**

With advancements in radiology, one could think of having non-invasive imaging (MRI, PET etc.) techniques to identify degenerated regions in the brain, such as substantia nigra, but the depletion is gradual which will go undetected in the early stages. Moreover, performing MRIs are too expensive to be carried out for a healthy population. Despite that, if someone wants to deploy imaging for early diagnosis, then it is necessitated to build some machine learning models (e.g., Deep learning methods such as Convolution Neural Networks etc.) for analyzing the whole brain regions that can be used for early diagnosis and predict the disease condition better than the existing models [12].

#### **2.3 Molecular markers-based diagnosis**

Metabolome-based analysis has been thriving in the last decade, and it is now extensively used for diagnosing PD using various sample matrices, such as

### *Early Diagnosis of Parkinson's Disease: Utility of Animal Models DOI: http://dx.doi.org/10.5772/intechopen.107887*

Cerebrospinal fluid metabolome, Blood metabolome, Tissue metabolome, Fecal metabolome, Urine metabolome. Although the initial metabolome results seem promising, it has some serious impediments to deal with, as the metabolome varies demographically and individually. Moreover, differences in genotype, presence of other diseases, lifestyle, diet, past medical records, and use of dissimilar tools and techniques for analysis enormously impact the results and conclusions. The reproducibility and validity of the results can be improved by standardizing the protocols, taking large samples, including various demographic populations in one study, and joint analysis with other methods. Among all, blood biomarkers are the most straightforward and cost-effective way of diagnosing a disease, but it does not seem to keep up to the mark in the case of PD. Heretofore, not a single biomarker has been found that can be employed universally in diagnosing the disease at the early stages. Many laboratories have conducted experiments relating to identification of circulating miRNAs, and they have come with a few novel miRNAs that are beneficial for early diagnosis of PD, but the results vary among the laboratories. This might be because of the difference in genotyping, symptoms, small sample size, demographic constraints, implementation of different protocols etc. Since miRNA can be collected aptly, if we improvise our approach, we can expect beneficial results. There is a dearth of rigorous standardization of the techniques, and one must address the above-mentioned challenges to improve the outcome. Nevertheless, different body fluids biomarkers such as αsynuclein aggregation or the formation of toxic tau isoforms are also considered hallmarks in PD. But they are deposited at the later stages of PD; therefore, they cannot be detected in the early stages and hence are not helpful for early diagnosis. There is a need to identify a biomarker that can be detected in the early stages of the disease. Scientists also contemplate a few miRNAs found in CSF as potential biomarkers, but sampling CSF is cumbersome and costly, and it also may lead to some untoward circumstances. Apart from CSF, it is required to identify miRNA from other body fluids, which can be collected easily and help diagnose the disease early [13, 14].

Few researchers have come up with machine learning (ML) models using various features to predict the disease condition. Several models focused on pre-motor symptoms of the disease and can predict the disease condition with acceptable accuracy. There is a need to tune the models with more data and play with other parameters and features, deploy other ML algorithms to improve the accuracy of the disease early diagnosis [15].

## **3. Challenges in early diagnosis**

PD begins much before the motor symptoms occur, also known as the Preclinical phase of the disease that may last several years. Symptoms of this phase include hyposmia, depression, anxiety, and sleep difficulties along with autonomic nervous system disorders such as digestion, breathing, salivation, bladder malfunction, excessive sweating, and sexual dysfunction [16]. Clinical PD begins with onset of motor symptoms such as resting tremors, bradykinesia, limb rigidity, and coordination issues. Symptoms usually proceed gradually, often starting on one side of the body, such as reduced one-sided arm swing and intermittent tremors. Cognitive impairment (a non-motor symptom) appears often after the motor symptoms [17]. Many patients with PD develop dementia, however the time frame varies significantly from one individual to another. Dementia is a primary reason for PD patients to enter long-term care facilities [18]. However, it has been observed that the onset of motor symptoms

i.e. clinical PD starts much earlier than it can be diagnosed with current diagnostic criteria. Hitherto, no biomarkers have been found which will assist accurate diagnosis of these conceptual phases of pre-diagnostic PD with high sensitivity and specificity [19].

Furthermore, it should be noted that perception of a PD case on early diagnosis may be significantly influenced by their demographics, their family history, or a genetically identical state [20]. However, there is also the possibility of entering in disease-modifying therapy trials associated with gene targeting. Along with the fact that different mutations for PD have been reported, exhibiting a varying degree of penetrance in various populations. As a result, while some populations are susceptible to one mutation, the same mutation may not be active as a risk factor for the development or progression of the disease in other populations. Genetic testing of unselected PD cohorts revealed that up to 10% of cases with Glucocerebrosidase gene A (GBA) mutations had type 1 GD (Gaucher's disease), which is known to dramatically enhance the risk of acquiring PD (and is considerably high in few populations, like Ashkenazi Jewish demography) [21, 22]. Leucine-rich repeat kinase 2 (LRRK2) gene mutations are present in a substantial number of PD patients in several groups, including Ashkenazi Jewish and Berber Arab communities [23–25]. Similarly, it has been discovered that Han Chinese people have a substantial association with GAK gene mutation [26].

Despite various studies, PD diagnosis and misclassification in routine clinical practice are frequent, with error rates between 15–24% [27–29]. Approximately 10% of cases that were diagnosed with PD by neurologists had alternate pathologies (like multiple system atrophy, tauopathies and progressive supranuclear palsy), despite the adoption of strict clinical diagnostic criteria [30]. A recent meta-analysis of 11 clinicopathological investigations revealed a shared accuracy in clinical diagnosis of PD cases of only 81% which is a reason why various forms of secondary parkinsonism and tremor diseases such as essential tremor, are frequently misdiagnosed as PD [31]. Early diagnostic separation of PD from atypical parkinsonian disorders presents the toughest challenge even for qualified professionals. Diseased defined by neuronal deposition of phosphorylated tau aggregates like tauopathies and progressive supranuclear palsy are among the parkinsonism disorders including multiple system atrophy which are pathologically characterized by presence of cytoplasmic glial inclusions formed due to aggregation of *α-synuclein* in oligodendrocytes. All these conditions can be exceedingly difficult to identify from one another and from PD in the early stages of the disease [32, 33]. According to clinicopathological research clinical diagnostic mistakes account for 7 to 35% of cases [34–36]. It is important to optimize the clinical biomarkers that can be used to differentiate between PD and these main subtypes of atypical degenerative parkinsonism.

To address this need, various cross-sectional case-control studies have strived to define the prognostic value of non-genetic, genetic risk and prodromal clinical factors (biomarkers identified from studies on animal models) to establish the probability of translation to clinically identified PD. Some of the studies which have been initiated to better characterize this using a variety of risk factors or markers and prodromal features are:

• The Parkinson's Associated Risk Study (PARS) is a multicentre study in the United States that compares older individuals with and without hyposmia and involves annual physical exams and twice-yearly dopamine transporter SPECT scans [37].


These cohorts offer valuable pre-diagnosis information from at-risk subjects who may experience PD in the course of study period or who have recently received a diagnosis. Studies based on these cohorts pay particular attention to the emergence of prodromal symptoms and epidemiologic traits based on biofluids or biopsies. However, a basic barrier in research on neurodegenerative diseases is the inability to characterize disease at molecular level and infer disease progression from these parameters [41]. Animal models are therefore necessary since they are the only way to directly and longitudinally analyze any disease-relevant tissue. Additionally, by standardizing and closely observing living conditions, they enable the assessment of environmental and behavioral influences on etiologically complicated disorders like PD.

In addition to identification of novel biomarkers for early and accurate diagnosis, better diagnostic methods are needed to identify PD earlier in the course of disease progression. By the time a patient exhibits clinical symptoms and is diagnosed with PD, neurons and autonomic nervous system functions have been lost. An earlier diagnosis may provide a therapeutic window to slow or alleviate PD before onset of motor deficits (**Figure 1**). Even with the varying methodologies, there is a clear indication with promising results which can detect cases with strong manifestation of "pre-diagnostic" PD via clinical, imaging, and other risk markers. As many of these cohorts mature, the numbers of "high-risk" individuals "converting" to established PD provide proof of concept and will assist to establish the optimum approach to "early" detection. We must redraft our strategy and amalgamate the above-mentioned approaches to early diagnose the disease with high accuracy, sensitivity, and specificity. If PD is detected at the early stages, disease progress can be slowed or at best can be halted, consequently reducing the economic burden and improve the quality of life.

Early PD diagnosis will be beneficial in many terms such as (i) Early diagnosis will give ample time to the patient, the caregivers, the family and the clinicians to understand the disease and to decide the course of treatment and plan their future goals

#### **Figure 1.**

*Parkinson's disease symptoms during the course of a human's life, both prodromal and clinical. Diagram illustrating the progression of life from early to old age and the related brain health curves in PD cases compared to the healthy condition. The distinctive motor phenotypes that show up in late stages of the disease are the basis for the current clinical diagnosis of PD. Contrary to the prodromal phase, which might last between 10 and 15 years, the length of the preclinical phase is unclear, as shown by the dotted arrow. A prodromal diagnosis of PD might be made by following altered molecular trajectories from preclinical to clinical stages, which would increase the positive effects of neuroprotective lifestyle modifications or available therapeutic alternatives.*

accordingly, (ii) It will help the patient to modify their lifestyle such that progression of the symptoms can be halted, a few non-drug treatments might be a possibility in that situation, (iii) Early diagnosis will improve the chance of cure for the disease, (iv) The classic drugs will be more effective in the patients whose symptoms have been detected at the early stages (v) Early diagnosis will reduce the economic burden on both the patient and the state.

## **4. Animal models in Parkinson's disease**

The animal model of PD has been extensively used to study the pathophysiology of PD progression and design new therapeutic intervention. Several models have been developed by various methods in model animals (rodents, non-human primates and non-mammalians) to recapitulate clinical phenotypic features and parkinsonian manifestations (**Table 1**). Highly reproducible models have occurred in rodent such as rats and mice due to their short life of span, low maintenance, and easy handling. There are two ways to culminate the PD model in animals: one is the systemic injection of PD-inducing drugs and the local administration of the drug (intracerebral, intracerebroventricular, intrastriatal, Intra-*SNpc*. Etc.) with the use of the stereotaxic instrument.

Over the last decade, the advent of the genetic era of PD gives out phenomenal insight into the genetic model of PD. These models are solemnly based on mammalian and non-mammalian transgenic models that propagate disease-causing mutation considered to be a monogenetic form of familial PD. Neurotoxic, herbicides, and


## *Early Diagnosis of Parkinson's Disease: Utility of Animal Models DOI: http://dx.doi.org/10.5772/intechopen.107887*

**Table 1.** *Advantages*

 *and* 

*disadvantages*

 *of various PD models in different animals.*

transgenic models have their characteristics and limitations, which must be taken very carefully chosen to be our model. Here, in particular, we discuss the neurotoxin-based model in rodent animals. There are many chemicals are being used in the development of PD such as MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) a prodrug that readily crosses the BBB due to its lipophilic nature. It is bound to complex 1 of electron transporter and reduces the conversion ATP from molecular oxygen, which consequently embarks the production of ROS, lipid peroxidation, irregular homeostasis in iron metabolism, and leads to cell death. MPTP has all hallmarks of PD in primates compared to non-primates. Therefore, MPTP could be the most suitable compound for PD development in Primates. Another, drug that has been used in the PD model is 6-hydroxy dopamine, it does not cross the BBB and consider non-systemic. So, it has to be injected directly into the SN region of the midbrain. Apart from the neurotoxin model herbicide and insecticide drugs are also used frequently in the development of PD such as Paraquat, and Rotenone. Transgenic models are also available in the form of monogenetic mutation. *α-synuclein* is abundantly expressed at 1% of total cytosolic brain protein. Overexpression of *α-synuclein* and its role in dopaminergic neurons has to be observed in the genetic model of PD. Mutation in α-synuclein, and LRRK2 leads to autosomal dominant disease while PINK, Parkin, and DJ1 are probably considered for Autosomal recessive disease.

### **4.1 Neurotoxin-based model in PD**

The emergence of technology and advancement of biological research revealed the reduced levels of Dopamine in the striatum region of PD in human patients opened the window of research and treatment interventions. There are several models of PD in animals that have been characterized by the low amount of Dopamine in the SN region and striatum. Many neurotoxins and herbicide compounds ameliorate ATP production subsequently leading to cell death. Deprivation of dopamine-producing neurons is directly proportional to the less amount of dopamine in the SN region. This vital characteristic seems to be a cardinal hallmark of PD in the various animal models.

## *4.1.1 MPTP-based PD model*

MPTP is a non-toxic, lipophilic compound that readily crosses the BBB. After entering the brain, especially in Astrocyte cells it metabolizes by monoamine oxidase B into MPP<sup>+</sup> (1-methyl-4-phenylpyridinium ion). MPP<sup>+</sup> enters in dopamineproducing neurons with the help of Dopamine transporter in *substantia nigra pars compacta* (*SNpc*) region. Active MPP+ binds to Complex1 of ETC and reduces ATP production [42]. This suggests that mitochondria are a preferential target of neurotoxicity. Administration of MPTP in primates through bilateral carotid injection causes L-DOPA responsive Parkinsonian syndrome characterized by all the clinical manifestations of PD which showed the best model of PD in Primates [43]. Intraperitoneally administration of MPTP in mice at certain doses (four MPTP every 2 hours. Over a day) gives the similar kind of lesions and phenotypic characters as in primates [44]. MPTP model has certain limitations such as, administration of MPTP in an animal model fails to mimic the progressive nature of PD [45]. Long term chronic treatments of MPTP may overcome this issue however, the smaller doses for long term resulted in the recovery of motor behavior deficit in animals when the treatment was discontinued. Another limitation of this model is that *SNpc* lesions are rarely accompanied by the formation of Lewy bodies [46].

## *4.1.2 6-Hydroxydopamine-based PD model*

6-Hydroxydopamine (6-OHDA) is a chemical compound that is also known as oxidopamine or structurally known as 2, 4,5 trihydroxy phenethylamine is the firstever generated PD model in animals [47]. This neurotoxin destroys the dopaminergic neurons in the *SNpc* region. 6-OHDA was a noble chemical compound that had a neurotoxic effect on catecholaminergic pathways [48]. Due to its lack of lipophilic nature 6-OHDA does not penetrate BBB hence it has to be directly administered stereotactically to a specific region of the brain such as *SNpc* or striatum. 6-OHDA effectively destroys the dopaminergic neurons in 12 hrs in the *SNpc* region while striatum-based neurons are conventionally lost within 2–3 days [49]. This kind of degeneration replicates the PD phenotypes. 6-OHDA agonistically binds to DA & NAT transporter respectively that facilitate to move inside of the cell where it autooxidizes in the cytoplasm, therefore, generating intracellular oxidative stress [50, 51]. 6-OHDA infused in neurons thus elevated cytotoxic molecules that are produced by an enzymatic and non-enzymatic process in which intrinsic trace element like Mg, and Fe is completely involved in cellular homeostasis [50, 52]. Moreover, 6OHDA generates H2O2 by the oxidation process in which it is highly toxic to cellular environments. Aside of its toxicity, it plays a vital role in free radicals' formation, ROS species, and quinone intermediate products [53]. Dopamine is a neurotransmitter and is metabolized into 6-OHDA. It acts as a neurotoxin and therefore produces lesions in the nigrostriatal pathway. In spite of that, 6-OHDA does not promote protein aggregation of alpha-synuclein protein with other fibrils, thus Lewy neurites inclusion bodies are not produced in 6-OHDA-based animal models [49].

## **4.2 Herbicides-based PD model**

Several reports suggest that farmers who are exposed to herbicides such as Rotenone and Paraquat suffered with symptoms similar to familial PD [54]. This finding suggests the role of this chemical in the development of the PD model in animals.

## *4.2.1 Paraquat-based PD model in animals*

Unlike MPTP, Paraquat (PQ) does not cross BBB, but it has a similar structure to MPP+ (an active metabolite of MPTP). Due to its structural resemblance, it behaves like MPP+. PQ acts through the involvement of the redox cycle and subsequently induces oxidative stress. Therefore, it produced Reactive oxygen species, particularly: superoxide radical, peroxide, and hydrogen radicals that lead to damage to lipid molecules, protein, DNA, and RNA. A recent study proposed dilemmatic evidence on paraquat exposure in rats. One report mentioned arbitrary statements chronic systemic injection of paraquat in mice reduced the motor activity and subsequently loss of the tyrosine hydroxylase-positive striatal fibers and *SNpc* neurons. On the other hand, Cory-Slechta et al. reported that prolonged treatment of PQ does not have any effect on the nigrostriatal DA region in mice model [55].

## *4.2.2 Rotenone-based PD model in animals*

Rotenone is a naturally occurring herbicide/insecticide. Its half-life is generally 3–5 days depending on the exposure to natural light. Like MPTP neurotoxin, Rotenone has similar chemical properties and crosses the BBB readily and uniformly inhibits the complex-1 of ETC [56] In this retro-aspect, MPTP inhibits dopaminergic neurons due to the dependence of the DAT transporter in dopaminergic neurons while Rotenone inhibits complex 1 selectively in the nigrostriatal dopaminergic pathway. Thus, Rotenone seems to recapitulate all kinds of PD hallmarks such as systemic complex 1 inhibition, inflammation, ubiquitin-*α-synuclein* aggregation in nigral cells that look like Lewy bodies in PD, oxidative stress, and GI problems [57]. Behaviorally, rotenone-treated rats have hypokinetic characteristics along with flexed posture similar to stooped posture in human PD patients. Few rats have severe rigidity and few have spontaneously shaken which is similar to a resting tremor. The existing beauty of this model is that like paraquat, it also introduced *α-synuclein* aggregation and Lewy body-like formation. The limitation of this model is that it does augment the DA oxidation but the evidence is narrow about the depletion of dopaminergic neurons in the nigrostriatal system [58].

## **4.3 Genetic model of PD**

According to Cedric Bardy (2020), 85% of the PD population are sporadic and the remaining are familial PD [59]. Familial PD is generally based on genetic defects that are counted as autosomal dominant (AD) or autosomal recessive (AR). *α-synuclein* gene (SNCA) and LRRK2 are experimentally proven to be involved in AD in Parkinson's Disease. *α-synuclein* is a small (14kD) protein, present abundantly in brain tissue, while a lesser tone of protein is present in the heart, muscle, and other tissue. Currently, its peculiar role is not clear but plays an important role in the membrane, vesicular dynamics, and intracellular trafficking within the ER/Golgi network. The identification of *α-synuclein* mutation was the first to be involved in familial PD thereafter many researchers try to overexpress in Drosophila and yeast resulting in that hampers the ER-Golgi network trafficking and toxic *α-synuclein* leads to neuropathology and amyloid aggregation in nigral cells which are the key features of familial PD [60, 61]. Mutations in *α-synuclein* create a high propensity for protein misfolding. *α-synuclein* exists in various structures including oligomers, protofibrils, fibrils, and, filaments. The amalgamation of filamentous and fibril structures seems to be a more toxic form [62]. Mashliah et al. (2000) developed the first-ever model using mutated SNCA (A53T, A30P, and E46K) and observed the inclusion kind of bodies in the hippocampus, *SNpc*, and neocortex region but they do not have any evidence of *αsynuclein* inclusion bodies like LB in human patients. Meanwhile, the same group had done another experiment to confirm the previous findings but unfortunately, the result was the same no dopaminergic neuron degeneration has been observed in mice [63]. Another group developed a double mutant (A30P, A53T) model in mice and apparent neurotrophy was reported. This key feature was retorted motor activity and promotes neuronal aggregates [63].

LRRK2 (leucine-rich repeat kinase 2) is a multidomain having 286 Kd protein. It is also known as dardarin and PARK8. One part of the dardarin protein that enriches the protein building block amino acid is known as leucine. LRRK2 is a large multimeric protein that is localized to an outer membranous structure. LRRK2 protein plays various roles in the cell but neuronal outgrowth and guidance [64]. Mutation in LRRK2 is associated with autosomal dominant PD with varying occurrence in the population [65]. The most common mutation is G2019S has a low frequency of 1% of sporadic PD patients while 4% of familial PD. The risk of PD in the person of LRRK2 G2019S is age-dependent: 28% at 59 years old, 51% at 69 years old 74% at 79 years old [66]. The two most important mutant model G2019S and R 1441C/G have failed to recapitulate the PD hallmarks. Przedborski, S.; et al., use BCA-R 1441C mutant mice to show motor deficit and axonal pathology in the striatum, however, loss of DA neurons in *SNpc* and alpha-synuclein is not seen clearly [67]. Another team developed the LRRK2 model using a viral vector-like Herp simplex virus (HSV) and an adenoviral vector. Transfection of G2019S is more effective than WTR1441C in stimulating neuronal pathology and Lewy body aggregation [68]. In Addition, infusion of HSV-LRRK2-G2019S in mouse striatum achieved 50% DA neuronal loss in the SN region [67, 69]. So, the LRRK2 model could provide a good platform to understand the neuropathology, mechanism of neuronal loss in the mid-brain region, and their function in PD.

## **5. Diagnostic biomarkers for PD**

Despite decades of research, PD is currently diagnosed primarily on motor symptoms. Majority of dopaminergic neurons are degenerated by the time PD is confirmed, complicating treatment. Due to intersection of symptoms between PD and other atypical parkinsonian disorder the misdiagnosis rates by the clinicians for PD are quite high. Misdiagnosis and delayed diagnosis undermine disease-modifying therapy. Therefore, identification and quantification of biomarkers are vital for evaluating individual physiological and clinical responses, supporting therapeutic decisions, defining treatment and management programs, and managing causes of individual or group changes. Although motor and non-motor symptoms are visible clinically, the brain pathology in humans can only be established by evaluating post-mortem tissue samples or body fluids. The use of humans as a PD model for the identification of early diagnostic biomarkers is complicated by the fact that we do not know the time of PD onset, which may span between 10 and 15 years [18]. This can be circumvented by utilizing animal models, as we can monitor them from the moment of neurotoxic injection until the onset of symptoms, as well as identify the molecular alterations preceding the onset of symptoms. In addition, the identification of markers from noninvasive or minimally invasive techniques necessitates the use of animal models for early diagnostics. Consequently, there is a huge demand for experimental models to enhance our comprehension. To date, however, only a handful of putative biomarkers have been tested in clinical settings.

## **5.1 Non-invasive biomarkers**

Two main techniques fluorodopa positron emission tomography (F-DOPA PET) and dopamine transporter single-photon emission computed tomography (DAT-SPECT) are used to measure the neurochemical differences dopamine system [70, 71]. Another technique called the susceptibility-weighted imaging (SWI) also works with high sensitivity and specificity on Nigrosome-1 (N1) cluster in differentiating PD from control and other non-PD parkinsonism [72]. An important prodromal PD marker is RBD which occurs at a high risk of 45% in early prodromal stages and 76% in late prodromal stages. As per a report on RBD cohort, 39.7% of RBD patients were found to develop PD or dementia with Lewy bodies. Another study on the same cohort, demonstrated the conversion of prodromal stages into PD with high sensitivity (81.3%) and a specificity (67.9%) [73, 74].

### **5.2 Invasive biomarkers**

Biomarkers obtained via invasive technique are blood-based biomarkers which include *α-synuclein*, Extracellular Vesicles, miRNAs and inflammation related biomarkers. *α-synuclein* is a promising biomarker that is a key protein found in the Lewy bodies. Its malformation and aggregation due to both post translational modification and genetic factors in PD is a good indicator of PD pathogenesis [75]. This pathogenic protein is mainly transported from cells to cells through extracellular vesicles which makes them a candidate to use as a biomarker. A study performed by Majbour et al. using Oligomeric α-synuclein/total *α-synuclein* in CSF was not able to classified PD from DATATOP cohort whereas Oligomeric α-synuclein/total α-synuclein, phosphorylated was able to distinguish PD from healthy controls by sensitivity and specificity of 79% and 67% respectively [76]. Another promising candidate are the miRNAs, which are a class of non-coding RNA and the combination of different biomarkers can readily differentiate PD from healthy cases. For example, a study performed by using MiR-19a, miR-19b, miR-24, miR-30c, miR-34b, miR-133b, and miR-205 from CSF classified PD from control cases with AUC of 0.98 [77]. In various studies it been stated that inflammation is a major deriver of PD and certain kinds of cytokines like TNF α, IL-1, IL-4, IL-6, and IL-10 are highly expressed in PD patients. In a recent study IFN-γ, IL-10, and TNF-α obtained from blood serum distinguished patient with cognitive impairment, postural instability and PD have high expression levels than in the control samples [78]. In recent times, gut-inflammation related biomarkers have also been discovered which are found to be linked with severe constipation and motor phenotype which includes high expression of TRL4, CD3+ T cells, and cytokines in colonic biopsies of PD patients [79].

Combination of above mentioned biomarkers can increase the sensitivity of prediction accuracy. Developing a system to aggregate the diverse types and intensities of these biomarkers into a single set of criteria is difficult. Plasma aggregated *α-synuclein* and various ESWAN imaging indicators were integrated in the prediction model of a cohort research, and it was revealed that it has a sensitivity and specificity of 0.80 and 0.80, respectively, for predicting PD [80]. Analysis of age with the combination of CSF oligomeric/total *α-synuclein* ratio and β-glucocerebrosidase activity distinguished PD cases from non-dementia cases with 82% sensitivity and 71% specificity [81]. Matsusue et al. used combination of imaging methods, including NM-MRI and DAT-SPECT, demonstrated a good diagnosis accuracy with an AUC of 0. 935 [82].

## **6. Utility of animal models**

As discussed in the earlier sections, PD is idiopathic with multiple genetic and environmental risk factors. In humans, motor symptoms are noticeable at advanced disease stages; the pathology starts much earlier than the diagnosing time. In these situations, animal models can play a vital role where we can induce such types of disease pathology and monitor the disease from the beginning. Motor and non-motor symptoms are easily detected, but brain pathology is only possible with post-mortem brain tissue. The heterogeneous nature of PD in terms of etiology & pathology demands a range of animal models [83]. Therefore, it is crucial to deepen our understanding through various experimental models to scale up the limited available treatment options. We need a diverse range of animal models to recapitulate different aspects of PD in humans. Thus studying PD with an appropriate animal model is very

## *Early Diagnosis of Parkinson's Disease: Utility of Animal Models DOI: http://dx.doi.org/10.5772/intechopen.107887*

important to understand the biology of disease in every aspect. Humans share most of the genetic information with different animals. There is about 96% genetic similarity between a human and a chimpanzee and 90% between humans and rats. Mouse shares about 85% of their genome with humans regarding protein-coding genes, while fruit fly shares about 61% of genetic information with humans. The handling and ease of propagation of these small animals make them valuable research tools.

Three categories of PD models are used in research so far. This includes rodents, non-human primates, and non-mammalian species [84]. By 2018 the major percentage of animal models used for PD is a rodent (85%), followed by non-human primates (10%) and non-mammalian species (5%). In another study, out of 1851 papers screened for PD, 996 used a mouse model followed by 805 rat model. Others include Drosophila-43, C. elegans-14, non-human primates-69, Chinese Hamster-6, Yeast-17, E.coli-6, Zebrafish-24, and others 27 [85]. These animal models and their advantages and disadvantages have been discussed briefly in the **Table 1**. The array of animal models available today ranges from small worms (nematodes) to flies (drosophila) to rodents (mice and rats) and primates (monkey and chimpanzee). The worms and flies model can be used to study individual pathological pathways. Still, when it comes to getting closer to the relevance of the human disease features, we need to switch to higher-order animals like rodents (mice or rats) or Primates (chimpanzees, gorillas, orangutans, etc.) [86].

Three different modeling pathologies are most common in the case of PD. These include Nigrostriatal tract degeneration, outside the nigrostriatal tract neuron dysfunction, and Lewy body pathology. Here we have summarized the different models and their respective modeling pathologies along with other features like Mitochondrial Dysfunction, Oxidative stress, Motor deficit, Cognitive deficit, Autophagy, Proteasomal Dysfunction, Neuroinflammation, Response to L-DOPA, Sensory abnormalities, Somnolescent alterations, Psychiatric Changes and Organ system dysfunction based on the latest review by Joana Lama (**Figure 2**) [87].

Small animal models and rodents partially replicate human PD's clinical and pathological features [88, 89]. In one of the studies, it has been reported that most transgenic rats show no dopaminergic neuron loss [90]. Rodent models have been widely used to model selective pathological pathways in PD like how the α-synuclein aggregate and spread, mitochondria damage and malfunction, faulty degradation of misfolded proteins, and immune system activation in PD state [91, 92]. As primates (chimpanzees, orangutans, etc.) are closer to humans than rodents, they classify as good models for identifying critical pathological events in humans than small animals. Higher-order animal models have played a key role in understanding PD so far [93]. In large animal models like the rhesus monkey, by expressing mutant α-synuclein in the fertilized embryos, the obtained progeny after 2.5 years show age-dependent nonmotor symptoms like anxiety, cognitive defects, poor dexterity, and finger coordination [94]. Monkeys with stereotaxically injected Lentiviral vectors carrying A53T mutant (A53T α-synuclein) in *substantia nigra* at differing ages disclosed that aging is the major factor that promotes neuropathology in non-human primate brain [95]. Thus, large transgenic animals provide us with critical information regarding neuropathology and disease pathogenesis which is difficult to understand from rodent models. With the latest gene-editing technology like CRISPR Cas9, large animal models for PD, like non-human primates, can be easily created with a genetic mutation in one of the critical PD genes to understand the disease's pathology better [93].

All the models discussed above have contributed significantly to understanding PD. But none of the models completely replicate PD in humans exactly. Neurotoxic


#### **Figure 2.**

*Occurrence of PD pathologies in different animal models.*

models are an excellent candidate because they replicate the nigrostriatal neurodegeneration and motor dysfunction but lack proper Lewy body formation. While transgenic animal models show Lewy body pathogenesis, but lacks the loss of dopaminergic neurons [96]. Many mutation studies have been performed in cell lines, but those results seem inconsistent. After the discovery that reduced dopamine levels was responsible for the motor symptoms in PD, most of the animal models focused on mimicking this dopamine loss through the use of neurotoxins. These animal studies led to the discovery of pathways related to the DA loss in *substantia nigra* and L-Dopa drug development for PD related motor symptoms treatment. But as discussed earlier, PD is a multifactorial disease that affects both CNS and PNS along with multiple organs like the gut, heart, skin, etc., and symptoms affecting these organs called the prodromal symptoms that appear much before the visible motor symptoms. These prodromal symptoms include hyposmia, constipation, hypertension, and sleep disorders which results due to the accumulation of *α-synuclein* pathology in the gut, skin, heart and lower brain regions. The prodromal phase act as a golden opportunity; if we can recapitulate and model animals in a way that mimics these symptoms, we can identify novel disease targets and treatments.

After the Braak's gut-first hypothesis [97], which states that the *α-synuclein* pathology first starts in the enteric nervous system decades before the motor symptoms start to appear and travels upto the brain stem and dopaminergic neurons through the vagus nerve, researchers started focusing on the gastrointestinal tract to model gut dysfunction in PD in animals [98, 99]. Other possible initiation sites have also been explored simultaneously for example targeting autonomic ganglia in mice

## *Early Diagnosis of Parkinson's Disease: Utility of Animal Models DOI: http://dx.doi.org/10.5772/intechopen.107887*

mimics hyposmia, orthostatic hypotension and constipation without any motor symptoms [100] whereas targeting lower brainstem regions mimics RBD, depression, and anxiety [101]. Many transgenic rodent models that express *α-synuclein* pathology through BAC vectors show RBD-like dysfunction without atonia and hyposmia and loss of dopaminergic neurons later [102]. BAC-developed mice with A30P *α-synuclein* mutation show gut dysfunction before motor dysfunction. *α-synuclein* preformed fibrils (PFFs) injected in GI tract in mice is one of the most successful animal model since it recapitulates symptoms like gut dysfunction, anxiety, and Dopaminergic neuron loss [98]. PFFs injected in RBD-responsible region of mice also results in RBDlike behavior followed by decreased olfaction, GI dysfunction, and motor deficits [101]. VMAT-2 deficient animal models show *α-synuclein* aggregation and later DA neuron loss with increased anxiety and reduced olfaction [103]. These prodromal models have helped us gain insights into the cellular and molecular mechanism of PD initiation and progression, but it is not specific and limited. Thus, we see a plethora of symptoms overlapping in different animal models.

One of the key risk factor for PD is aging but majority of animal model used, are quite young which fail to relate to the cellular and molecular metabolism to this age. However certain studies compare treatment between young and old age animals, and have shown that the treatments are not so effective in old animals. The heterogenic nature of PD is seen in symptoms wherein some patients experience dementia much earlier than others. Pathological characters of PD include existence of *α-synuclein* Lewy bodies and loss of Lewy neurites and nigrostriatal dopaminergic pathway. But these pathologies are not restricted to only CNS but are spread outside CNS, which is extremely difficult to model in animals. Though the neurotoxin model has helped us study the dopaminergic system in PD, it is not similar to studying the complex pathology, temporal progression, and clinical expression seen in human PD. Likewise, overexpression studies of *α-synuclein* can explain its functions and other effects because of its overexpression in that part. However in PD cases with normal expression level of *α-synuclein,* the question remains unanswered through these models. Transgenic animal models are good in indicating about a particular gene or protein function, but that does not necessarily mean studying PD. Similarly, injecting *αsynuclein* PFF explains the seed pathology in that area and how it spreads, but the same pathology is seen is human PD is still not proved [104, 105]. Thus all these models failed to recapitulate the age of onset of disease, the spectrum of pathologies, and the temporal pattern of disorder similar to PD in humans. These models, as such cannot help us in understanding human PD's core pathologies to treat the sporadic form of the disease. One such example is GDNF, which is used in rodents and non-human primates to recover the loss of dopaminergic neuron system but when tried in human PD patient was unsuccessful. It was also shown that in the *α-synuclein* PD model, this toxin protein interfere with the GDNF signaling pathway indicating the clinical efficacy of these models [106, 107]. Thus we can say that animals can be used to model only specific pathologies of PD but not the disease as it is. Since animal models and humans represent two different disease states, the therapies that work on animals do not necessarily work on humans.

Despite these limitations, animal models have not failed us. From the starting, these models have helped to develop previous and current drugs and treatments. For example, reserpine-treated rats and rabbits helped develop L-DOPA therapy, the rodent neurotoxin model helped develop dopamine-receptor antagonists, and MPTPtreated monkeys have paved the path of identifying sub-thalamic nucleus for deep brain stimulation therapy. This led to the fascinating first L-DOPA trial in human PD

patients in 1961–1962 only in a window of 5 years of animal experimentation [108]. The prosecution was proposed based on three simple observations (i) a single shot of L-DOPA can reverse the sedative effect of reserpine in rats and mice [109], (ii) striatum harbors the highest amount of brain dopamine [110], and (iii) reduction of dopamine levels in caudate nucleus and putamen of Parkinsonian patients [111]. This happened much before the discovery of the neurotoxin PD animal model. It also led to the discovery of a variety of dopaminergic drugs and DBS (Deep Brain Stimulation). In 1997 *α-synuclein* pathogenesis was discovered, which enlisted PD in the category of protein misfolded disease. So accordingly, the disease modeling has also changed and adapted with time. Therefore, a single model no longer can serve the purpose, and even though the neurotoxin model is beneficial, it must be accompanied by models replicating the disease pathology and its progression. Appropriately using the currently available animal models can lead to new drug interventions. Though they are expensive and time-consuming, when it comes to the ethical background, only animal models can be used for preclinical trials. PD patient-derived stem cells and organoid culture are promising concepts, but they cannot replace the need for animal trials.

It is challenging to amalgamate all the complex biochemical pathways of PD in one animal model; therefore, we can use different models for different pathological aspects of PD. Thus the utility of animal models is indispensable for PD research. But there is no single model that can be used in all conditions. We need to choose the appropriate animal models according to our needs.

## **7. Conclusion**

The early diagnosis of PD is still a major challenge as PD symptoms are very specific to human particularly in the later stage of the disease at which the PD is typically diagnosed in the patients. Diagnosis in early/prodromal stage is difficult due to the inaccessibility of patients. The use of` animal in PD research an also be debated considering the accuracy of the results in animal and human subject. Broadly we can categories the use of animal in PD research in two categories on the basis of purpose of the study i.e. either to develop new therapeutic interventions or to discover novel biomarkers for early diagnosis. Roger A. Barker and Anders Bjorklund (2020), discussed two sides of using animal model in PD. Barker discusses why the animal models are not useful and it is waste of resources on the other hand Anders Bjorklund explains the how the animal models are significantly useful and provide good insights for PD [112]. For therapeutic purpose the use of animal can be debated but for studies intended to discover early diagnostic marker the use of animal models appear to be the best choice. Despite of several failed attempt and the diversity of PD progression between animal models and human, cannot be the reason not use the animal models for further PD research particularly to identify early diagnostic markers. To discover the early diagnostic markers it necessary to have the case and control data from human subject. The major challenge in this step is that it is difficult to have early stage data from human subject because of inaccessibility of the PD patients at prodromal stage. PD is clinically diagnosed in human patients only when motor symptoms appear and has passed the prodromal stage nearly a decade before. Even if we collect the data from patients at prodromal stage it is difficult to say that they are going to show PD in future, which would again take years to develop. Also the symptoms at prodromal stage are very common to other ailments and overlap with the normal aging symptoms. For this reason using animal model has always been a best choice to study the

early changes in the group of subject which are given a specific treatment to develop PD. The group of animals subjected to the PD induction can be monitored from very early stage and compared with the control group of similar age.

## **Acknowledgements**

We acknowledge UGC-SAP to the Department of Biotechnology & Bioinformatics, School of Life Sciences, University of Hyderabad, for providing necessary support and infrastructure. We also acknowledge IoE Phase-II, University of Hyderabad (Grant no. 97020066) and DBT, India (No. BT/PR25787/GET/119/96/2017. We also acknowledge DBT, CSIR, UGC, and ICMR for provide fellowship to the NS, MZA, BK and MA respectively.

## **Conflict of interest**

The authors declare no conflict of interest.

## **Acronyms and abbreviations**


## **Author details**

Neha S†, Mohammad Ahmad†, Baby Kumari†, MD. Zainul Ali† and Pankaj Singh Dholaniya\*† Department of Biotechnology and Bioinformatics, School of Life Sciences, University of Hyderabad, Hyderabad, India

\*Address all correspondence to: pankaz@uohyd.ac.in

† These authors contributed equally.

© 2022 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Early Diagnosis of Parkinson's Disease: Utility of Animal Models DOI: http://dx.doi.org/10.5772/intechopen.107887*

## **References**

[1] Dorsey ER, Sherer T, Okun MS, Bloemd BR. The emerging evidence of the Parkinson pandemic. Journal of Parkinson's Disease. 2018;**8**:S3-S8. DOI: 10.3233/JPD-181474

[2] Yang W, Hamilton JL, Kopil C, Beck JC, Tanner CM, Albin RL, et al. Current and projected future economic burden of Parkinson's disease in the U.S. NPJ Parkinsons Disease. 2020;**6**:6-15. DOI: 10.1038/s41531-020-0117-1

[3] Marsden CD. Parkinson's disease. Lancet. 1990;**335**:948-949. DOI: 10.1016/0140-6736(90)91006-V

[4] Jennings D, Siderowf A, Stern M, Seibyl J, Eberly S, Oakes D, et al. Conversion to Parkinson disease in the PARS Hyposmic and dopamine transporter-deficit prodromal cohort. JAMA Neurology. 2017;**74**: 933-940. DOI: 10.1001/ JAMANEUROL.2017.0985

[5] Postuma RB, Gagnon JF, Bertrand JA, Génier Marchand D, Montplaisir JY. Parkinson risk in idiopathic REM sleep behavior disorder: Preparing for neuroprotective trials. Neurology. 2015; **84**:1104-1113. DOI: 10.1212/ WNL.0000000000001364

[6] Postuma RB, Berg D. Advances in markers of prodromal Parkinson disease. Nature Reviews. Neurology. 2016;**12**: 622-634. DOI: 10.1038/ NRNEUROL.2016.152

[7] Noyce AJ, Bestwick JP, Silveira-Moriyama L, Hawkes CH, Giovannoni G, Lees AJ, et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Annals of Neurology. 2012;**72**:893-901. DOI: 10.1002/ANA.23687

[8] Ugrumov M. Development of early diagnosis of Parkinson's disease: Illusion or reality? CNS Neuroscience & Therapeutics. 2020;**26**:997-1009. DOI: 10.1111/CNS.13429

[9] Haehner A, Boesveldt S, Berendse HW, Mackay-Sim A, Fleischmann J, Silburn PA, et al. Prevalence of smell loss in Parkinson's disease—A multicenter study. Parkinsonism & Related Disorders. 2009;**15**:490-494. DOI: 10.1016/J. PARKRELDIS.2008.12.005

[10] Haehner A, Masala C, Walter S, Reichmann H, Hummel T. Incidence of Parkinson's disease in a large patient cohort with idiopathic smell and taste loss. Journal of Neurology. 2019;**266**: 339-345. DOI: 10.1007/S00415-018- 9135-X

[11] Murphy C, Schubert CR, Cruickshanks KJ, Klein BEK, Klein R, Nondahl DM. Prevalence of olfactory impairment in older adults. JAMA. 2002; **288**:2307-2312. DOI: 10.1001/ JAMA.288.18.2307

[12] Zhang J. Mining imaging and clinical data with machine learning approaches for the diagnosis and early detection of Parkinson's disease. NPJ Parkinsons Disease. 2022;**8**:13\_1-13\_15. DOI: 10.1038/s41531-021-00266-8

[13] Shao Y, Le W. Recent advances and perspectives of metabolomics-based investigations in Parkinson's disease. Molecular Neurodegeneration. 2019;**14**: 3(1)-3(12). DOI: 10.1186/s13024-018- 0304-2

[14] Agrawal M, Biswas A. Molecular diagnostics of neurodegenerative disorders. Frontiers in Molecular

Biosciences. 2015;**2**:54(1)-54(10). DOI: 10.3389/fmolb.2015.00054

[15] Loh HW, Hong W, Ooi CP, Chakraborty S, Barua PD, Deo RC, et al. Application of deep learning models for automated identification of Parkinson's disease: A review (2011-2021). Sensors. 2021;**21**:7034(1)-7034(25). DOI: 10.3390/ s21217034

[16] Schrag A, Horsfall L, Walters K, Noyce A, Petersen I. Prediagnostic presentations of Parkinson's disease in primary care: A case-control study. The Lancet Neurology. 2015;**14**:57-64. DOI: 10.1016/S1474-4422(14)70287-X

[17] Cabreira V, Massano J. Parkinson's disease: Clinical review and update. Acta Medica Portuguesa. 2019;**32**:661-670. DOI: 10.20344/AMP.11978

[18] Kalia L, v., Lang AE. Parkinson's disease. Lancet. 2015;**386**:896-912. DOI: 10.1016/S0140-6736(14)61393-3

[19] Kilzheimer A, Hentrich T, Burkhardt S, Schulze-Hentrich JM. The challenge and opportunity to diagnose Parkinson's disease in midlife. Frontiers in Neurology. 2019;**10**:1328(1)-1328(9). DOI: 10.3389/FNEUR.2019.01328

[20] Bandres-Ciga S, Diez-Fairen M, Kim JJ, Singleton AB. Genetics of Parkinson's disease: An introspection of its journey towards precision medicine. Neurobiology of Disease. 2020;**137**: 104782(1)-104782(9). DOI: 10.1016/j. nbd.2020.104782

[21] Riboldi GM, Fonzo AB Di. GBA, Gaucher disease, and Parkinson's disease: From genetic to clinic to new therapeutic approaches. Cells. 2019;**8**:364(1)-364(16). DOI: 10.3390/cells8040364

[22] Beavan M, McNeill A, Proukakis C, Hughes DA, Mehta A, Schapira AHV. Evolution of prodromal clinical markers of Parkinson disease in a GBA mutationpositive cohort. JAMA Neurology. 2015; **72**:201-208. DOI: 10.1001/ JAMANEUROL.2014.2950

[23] Mirelman A, Alcalay RN, Saunders-Pullman R, Yasinovsky K, Thaler A, Gurevich T, et al. Nonmotor symptoms in healthy Ashkenazi Jewish carriers of the G2019S mutation in the LRRK2 gene. Movement Disorders. 2015;**30**:981-986. DOI: 10.1002/MDS.26213

[24] Gatto EM, Parisi V, Converso DP, Poderoso JJ, Carreras MC, Martí-Massó JF, et al. The LRRK2 G2019S mutation in a series of Argentinean patients with Parkinson's disease: Clinical and demographic characteristics. Neuroscience Letters. 2013;**537**:1-5. DOI: 10.1016/J.NEULET.2013.01.011

[25] Gunzler SA, Riley DE, Chen SG, Tatsuoka CM, Johnson WM, Mieyal JJ, et al. Motor and non-motor features of Parkinson's disease in LRRK2 G2019S carriers versus matched controls. Journal of the Neurological Sciences. 2018;**388**: 203-207. DOI: 10.1016/J.JNS.2018.03.025

[26] Zhang J, Zeng H, Zhu L, Deng L, Fang X, Deng X, et al. The potential mutation of GAK gene in the typical sporadic Parkinson's disease from the Han population of Chinese mainland. Molecular Neurobiology. 2016;**53**: 7119-7136. DOI: 10.1007/S12035-015- 9595-2

[27] Schrag A, Ben-Shlomo Y, Quinn N. How valid is the clinical diagnosis of Parkinson's disease in the community? Journal of Neurology, Neurosurgery, and Psychiatry. 2002;**73**:529-534. DOI: 10.1136/JNNP.73.5.529

[28] Rajput AH, Rajput A. Accuracy of Parkinson disease diagnosis unchanged in 2 decades. Neurology. 2014;**83**:

*Early Diagnosis of Parkinson's Disease: Utility of Animal Models DOI: http://dx.doi.org/10.5772/intechopen.107887*

386-387. DOI: 10.1212/ WNL.0000000000000653

[29] Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinicopathological study of 100 cases. Journal of Neurology, Neurosurgery, and Psychiatry. 1992;**55**:181-184. DOI: 10.1136/JNNP.55.3.181

[30] Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson's disease. Lancet Neurology. 2021;**20**:385-397. DOI: 10.1016/ S1474-4422(21)00030-2

[31] Rizzo G, Copetti M, Arcuti S, Martino D, Fontana A, Logroscino G. Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis. Neurology. 2016;**86**: 566-576. DOI: 10.1212/ WNL.0000000000002350

[32] Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, et al. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Movement Disorders. 2017;**32**:853-864. DOI: 10.1002/MDS.26987

[33] Wenning GK, Litvan I, Tolosa E. Milestones in atypical and secondary Parkinsonisms. Movement Disorders. 2011;**26**:1083-1095. DOI: 10.1002/ MDS.23713

[34] Koga S, Aoki N, Uitti RJ, van Gerpen JA, Cheshire WP, Josephs KA, et al. When DLB, PD, and PSP masquerade as MSA: An autopsy study of 134 patients. Neurology. 2015;**85**: 404-412. DOI: 10.1212/ WNL.0000000000001807

[35] Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist

movement disorder service. Brain. 2002; **125**:861-870. DOI: 10.1093/BRAIN/ AWF080

[36] Adler CH, Beach TG, Hentz JG, Shill HA, Caviness JN, Driver-Dunckley E, et al. Low clinical diagnostic accuracy of early vs advanced Parkinson disease: Clinicopathologic study. Neurology. 2014;**83**:406-412. DOI: 10.1212/ WNL.0000000000000641

[37] Jennings D, Siderowf A, Stern M, Seibyl J, Eberly S, Oakes D, et al. Imaging prodromal Parkinson disease: The Parkinson associated risk syndrome study. Neurology. 2014;**83**:1739-1746. DOI: 10.1212/WNL.000000000000 0960

[38] Berg D, Godau J, Seppi K, Behnke S, Liepelt-Scarfone I, Lerche S, et al. The PRIPS study: Screening battery for subjects at risk for Parkinson's disease. European Journal of Neurology. 2013;**20**: 102-108. DOI: 10.1111/J.1468-1331.2012. 03798.X

[39] Gaenslen A, Wurster I, Brockmann K, Huber H, Godau J, Faust B, et al. Prodromal features for Parkinson's disease—Baseline data from the TREND study. European Journal of Neurology. 2014;**21**:766-772. DOI: 10.1111/ENE.12382

[40] Marek K, Jennings D, Lasch S, Siderowf A, Tanner C, Simuni T, et al. The Parkinson progression marker initiative (PPMI). Progress in Neurobiology. 2011;**95**:629-635. DOI: 10.1016/J.PNEUROBIO.2011. 09.005

[41] Rees RN, Acharya AP, Schrag A, Noyce AJ. An early diagnosis is not the same as a timely diagnosis of Parkinson's disease. F1000Research. 2018;**7**:1106(1)- 1106(9). DOI: 10.12688/f1000research. 14528.1

[42] Annepu J, Ravindranath V. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineinduced complex I inhibition is reversed by disulfide reductant, dithiothreitol in mouse brain. Neuroscience Letters. 2000; **289**:209-212. DOI: 10.1016/S0304-3940 (00)01300-8

[43] Elsworth JD, Deutch AY, Redmond DE, Sladek JR, Roth RH. Effects of 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP) on catecholamines and metabolites in primate brain and CSF. Brain Research. 1987;**415**:293-299. DOI: 10.1016/ 0006-8993(87)90211-3

[44] Peña-Oliver Y, Buchman VL, Stephens DN. Lack of involvement of alpha-synuclein in unconditioned anxiety in mice. Behavioural Brain Research. 2010;**209**:234-240. DOI: 10.1016/J.BBR.2010.01.049

[45] Bhathena SJ. Comparison of effects of decapitation and anesthesia on metabolic and hormonal parameters in Sprague-Dawley rats. Life Sciences. 1992;**50**:1649-1655. DOI: 10.1016/ 0024-3205(92)90451-T

[46] Fornai F, Lenzi P, Ferrucci M, Lazzeri G, di Poggio AB, Natale G, et al. Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice. Brain Research Bulletin. 2005; **65**:405-413. DOI: 10.1016/J. BRAINRESBULL.2005.02.022

[47] Behavioral, Physiological, and Neurochemical Changes after 6-Hydroxydopamine-Induced Degeneration of the Nigro-Striatal Dopamine Neurons—PubMed. n.d. Available from: https://pubmed.ncbi. nlm.nih.gov/4531217/ [Accessed: July 14, 2022]

[48] Hernandez-Baltazar D, Zavala-Flores LM, Villanueva-Olivo A. The 6 hydroxydopamine model and parkinsonian pathophysiology: Novel findings in an older model. Neurologia (Barcelona, Spain). 2017;**32**:533-539. DOI: 10.1016/J.NRL.2015.06.011

[49] Blandini F, Armentero MT. Animal models of Parkinson's disease. The FEBS Journal. 2012;**279**:1156-1166. DOI: 10.1111/J.1742-4658.2012.08491.X

[50] Cadet JL, Brannock C. Free radicals and the pathobiology of brain dopamine systems. Neurochemistry International. 1998;**32**:117-131. DOI: 10.1016/ S0197-0186(97)00031-4

[51] Blum K, Febo M, Badgaiyan RD, Braverman ER, Dushaj K, Li M, et al. Neuronutrient amino-acid therapy protects against reward deficiency syndrome: Dopaminergic key to homeostasis and neuroplasticity. Current Pharmaceutical Design. 2016;**22**: 5837-5854. DOI: 10.2174/ 1381612822666160719111346

[52] Ostrerova N, Petrucelli L, Farrer M, Mehta N, Choi P, Hardy J, et al. Alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. The Journal of Neuroscience. 1999;**19**: 5782-5791. DOI: 10.1523/ JNEUROSCI.19-14-05782.1999

[53] Itier JM, Ibáñez P, Mena MA, Abbas N, Cohen-Salmon C, Bohme GA, et al. Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Human Molecular Genetics. 2003;**12**:2277-2291. DOI: 10.1093/HMG/DDG239

[54] Brown TP, Rumsby PC, Capleton AC, Rushton L, Levy LS. Pesticides and Parkinson's disease—Is there a link? Environmental Health

*Early Diagnosis of Parkinson's Disease: Utility of Animal Models DOI: http://dx.doi.org/10.5772/intechopen.107887*

Perspectives. 2006;**114**:156-164. DOI: 10.1289/EHP.8095

[55] Thiruchelvam M, Brockel BJ, Richfield EK, Baggs RB, Cory-Slechta DA. Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: Environmental risk factors for Parkinson's disease? Brain Research. 2000;**873**:225-234. DOI: 10.1016/S0006-8993(00) 02496-3

[56] Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov A, v., Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nature Neuroscience. 2000;**3**:1301-1306. DOI: 10.1038/81834

[57] Greenamyre JT, Cannon JR, Drolet R, Mastroberardino PG. Lessons from the rotenone model of Parkinson's disease. Trends in Pharmacological Sciences. 2010;**31**:141-142. DOI: 10.1016/ J.TIPS.2009.12.006

[58] Wu YN, Johnson SW. Dopamine oxidation facilitates rotenone-dependent potentiation of N-methyl-D-aspartate currents in rat substantia nigra dopamine neurons. Neuroscience. 2011; **195**:138-144. DOI: 10.1016/J. NEUROSCIENCE.2011.08.041

[59] Tran J, Anastacio H, Bardy C. Genetic predispositions of Parkinson's disease revealed in patient-derived brain cells. NPJ Parkinsons Disease. 2020;**6**: 8(1)-8(18). DOI: 10.1038/s41531-020- 0110-8

[60] Bell S, Rousseau J, Peng H, Aouabed Z, Priam P, Theroux JF, et al. Mutations in ACTL6B cause neurodevelopmental deficits and epilepsy and Lead to loss of dendrites in human neurons. American Journal of

Human Genetics. 2019;**104**:815-834. DOI: 10.1016/J.AJHG.2019.03.022

[61] Lautenschläger J, Stephens AD, Fusco G, Ströhl F, Curry N, Zacharopoulou M, et al. C-terminal calcium binding of *α-synuclein* modulates synaptic vesicle interaction. Nature Communications. 2018;**9**:712(1)-712(13). DOI: 10.1038/s41467-018-03111-4

[62] Lee VMY, Trojanowski JQ. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: New targets for drug discovery. Neuron. 2006;**52**:33-38. DOI: 10.1016/J. NEURON.2006.09.026

[63] Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, et al. Dopaminergic loss and inclusion body formation in alphasynuclein mice: Implications for neurodegenerative disorders. Science. 2000;**287**:1265-1269. DOI: 10.1126/ SCIENCE.287.5456.1265

[64] Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke—PubMed n.d. Available from: https://pubmed.ncbi. nlm.nih.gov/29786478/ [Accessed: July 14, 2022]

[65] Cilia R, Siri C, Rusconi D, Allegra R, Ghiglietti A, Sacilotto G, et al. LRRK2 mutations in Parkinson's disease: Confirmation of a gender effect in the Italian population. Parkinsonism & Related Disorders. 2014;**20**:911-914. DOI: 10.1016/J.PARKRELDIS.2014. 04.016

[66] Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: A case-control study. Lancet Neurology. 2008;**7**:583-590. DOI: 10.1016/S1474-4422(08)70117-0

[67] Li Y, Liu W, Oo TF, Wang L, Tang Y, Jackson-Lewis V, et al. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nature Neuroscience. 2009;**12**:826-828. DOI: 10.1038/NN.2349

[68] Alessi DR, Sammler E. LRRK2 kinase in Parkinson's disease. Science. 1979; **2018**(360):36-37. DOI: 10.1126/science. aar5683

[69] Lee BD, Shin JH, Vankampen J, Petrucelli L, West AB, Ko HS, et al. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nature Medicine. 2010;**16**: 998-1000. DOI: 10.1038/NM.2199

[70] Bajaj N, Hauser RA, Grachev ID. Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes. Journal of Neurology, Neurosurgery, and Psychiatry. 2013;**84**:1288-1295. DOI: 10.1136/JNNP-2012-304436

[71] Suwijn SR, van Boheemen CJM, de Haan RJ, Tissingh G, Booij J, de Bie RMA. The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson's disease or clinically uncertain parkinsonism: A systematic review. EJNMMI Research. 2015;**5**: 12(1)-12(8). DOI: 10.1186/s13550-015- 0087-1

[72] Calloni SF, Conte G, Sbaraini S, Cilia R, Contarino VE, Avignone S, et al. Multiparametric MR imaging of Parkinsonisms at 3 tesla: Its role in the differentiation of idiopathic Parkinson's disease versus atypical parkinsonian disorders. European Journal of

Radiology. 2018;**109**:95-100. DOI: 10.1016/J.EJRAD.2018.10.032

[73] Fereshtehnejad SM, Montplaisir JY, Pelletier A, Gagnon JF, Berg D, Postuma RB. Validation of the MDS research criteria for prodromal Parkinson's disease: Longitudinal assessment in a REM sleep behavior disorder (RBD) cohort. Movement Disorders. 2017;**32**:865-873. DOI: 10.1002/MDS.26989

[74] Iranzo A, Tolosa E, Gelpi E, Molinuevo JL, Valldeoriola F, Serradell M, et al. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eyemovement sleep behaviour disorder: An observational cohort study. Lancet Neurology. 2013;**12**:443-453. DOI: 10.1016/S1474-4422(13)70056-5

[75] Fayyad M, Salim S, Majbour N, Erskine D, Stoops E, Mollenhauer B, et al. Parkinson's disease biomarkers based on α-synuclein. Journal of Neurochemistry. 2019;**150**:626-636. DOI: 10.1111/JNC.14809

[76] Majbour NK, Vaikath NN, van Dijk KD, Ardah MT, Varghese S, Vesterager LB, et al. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease. Molecular Neurodegeneration. 2016;**11**:7(2)-7(15). DOI: 10.1186/ s13024-016-0072-9

[77] Marques TM, Kuiperij HB, Bruinsma IB, van Rumund A, Aerts MB, Esselink RAJ, et al. MicroRNAs in cerebrospinal fluid as potential biomarkers for Parkinson's disease and multiple system atrophy. Molecular Neurobiology. 2017;**54**:7736-7745. DOI: 10.1007/S12035-016-0253-0

[78] Rathnayake D, Chang T, Udagama P. Selected serum cytokines and nitric oxide *Early Diagnosis of Parkinson's Disease: Utility of Animal Models DOI: http://dx.doi.org/10.5772/intechopen.107887*

as potential multi-marker biosignature panels for Parkinson disease of varying durations: A case-control study. BMC Neurology. 2019;**19**:56(1)-56(10). DOI: 10.1186/s12883-019-1286-6

[79] Perez-Pardo P, Dodiya HB, Engen PA, Forsyth CB, Huschens AM, Shaikh M, et al. Role of TLR4 in the gut-brain axis in Parkinson's disease: A translational study from men to mice. Gut. 2019;**68**:829-843. DOI: 10.1136/ GUTJNL-2018-316844

[80] Chen XQ, Niu JP, Peng RQ, Song YH, Xu N, Zhang YW. The early diagnosis of Parkinson's disease through combined biomarkers. Acta Neurologica Scandinavica. 2019;**140**:268-273. DOI: 10.1111/ANE.13140

[81] Parnetti L, Chiasserini D, Persichetti E, Eusebi P, Varghese S, Qureshi MM, et al. Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease. Movement Disorders. 2014;**29**:1019-1027. DOI: 10.1002/MDS.25772

[82] Matsusue E, Fujihara Y, Tanaka K, Aozasa Y, Shimoda M, Nakayasu H, et al. The utility of the combined use of 123 I-FP-CIT SPECT and neuromelanin MRI in differentiating Parkinson's disease from other parkinsonian syndromes. Acta Radiologica. 2019;**60**: 230-238. DOI: 10.1177/0284185118 778871

[83] Foltynie T, Brayne C, Barker RA. The heterogeneity of idiopathic Parkinson's disease. Journal of Neurology. 2002;**249**:138-145. DOI: 10.1007/PL00007856

[84] Stoker TB, Greenland JC. Parkinson's Disease: Pathogenesis and Clinical Aspects [Internet]. Codon Publications; 2018. DOI: 10.15586/

codonpublications.parkinsons disease.2018. Available from: https://pub med.ncbi.nlm.nih.gov/30702835/

[85] Aerts L, Miccoli B, Delahanty A, Witters H, Verstraelen S, Strooper B De, et al. Do we still need animals? Surveying the role of animalfree models in Alzheimer's and Parkinson's disease research. The EMBO Journal. 2022;**41**: 1-8. DOI: 10.15252/embj.2021110002

[86] Breger LS, Fuzzati Armentero MT. Genetically engineered animal models of Parkinson's disease: From worm to rodent. The European Journal of Neuroscience. 2019;**49**:533-560. DOI: 10.1111/EJN.14300

[87] Lama J, Buhidma Y, Fletcher EJR, Duty S. Animal models of Parkinson's disease: A guide to selecting the optimal model for your research. Neuronal. Signals. 2021;**5**:1-24. DOI: 10.1042/ NS20210026

[88] Schwarting RKW, Huston JP. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Progress in Neurobiology. 1996;**50**:275-331. DOI: 10.1016/S0301-0082(96)00040-8

[89] Bugos O, Bhide M, Zilka N. Beyond the rat models of human neurodegenerative disorders. Cellular and Molecular Neurobiology. 2009;**29**: 859-869. DOI: 10.1007/S10571-009-9367-5

[90] Beal MF. Parkinson's disease: A model dilemma. Nature. 2010;**466**: S8-S10. DOI: 10.1038/466S8a

[91] Cenci MA, Björklund A. Animal models for preclinical Parkinson's research: An update and critical appraisal. Progress in Brain Research. 2020;**252**:27-59. DOI: 10.1016/BS. PBR.2020.02.003

[92] Jiang P, Dickson DW. Parkinson's disease: Experimental models and reality. Acta Neuropathologica. 2018;**135**: 13-32. DOI: 10.1007/S00401-017-1788-5

[93] Tu Z, Yang W, Yan S, Guo X, Li X-J. CRISPR/Cas9: A powerful genetic engineering tool for establishing large animal models of neurodegenerative diseases. Molecular Neurodegeneration. 2015;**10**:35(1)-35(8). DOI: 10.1186/ s13024-015-0031-x

[94] Niu Y, Guo X, Chen Y, Wang CE, Gao J, Yang W, et al. Early Parkinson's disease symptoms in *α-synuclein* transgenic monkeys. Human Molecular Genetics. 2015;**24**:2308-2317. DOI: 10.1093/HMG/DDU748

[95] Yang W, Wang G, Wang CE, Guo X, Yin P, Gao J, et al. Mutant alphasynuclein causes age-dependent neuropathology in monkey brain. The Journal of Neuroscience. 2015;**35**: 8345-8358. DOI: 10.1523/ JNEUROSCI.0772-15.2015

[96] Potashkin JA, Blume SR, Runkle NK. Limitations of animal models of Parkinson's disease. Parkinson's Disease. 2010;**2011**:658083(1)-658083(8). DOI: 10.4061/2011/658083

[97] Holmqvist S, Chutna O, Bousset L, Aldrin-Kirk P, Li W, Björklund T, et al. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathologica. 2014;**128**:805-820. DOI: 10.1007/ S00401-014-1343-6

[98] Kim S, Kwon SH, Kam TI, Panicker N, Karuppagounder SS, Lee S, et al. Transneuronal propagation of pathologic *α-synuclein* from the gut to the brain models Parkinson's disease. Neuron. 2019;**103**:627-641.e7. DOI: 10.1016/J.NEURON.2019. 05.035

[99] van den Berge N, Ferreira N, Mikkelsen TW, Alstrup AKO, Tamgüney G, Karlsson P, et al. Ageing promotes pathological alpha-synuclein propagation and autonomic dysfunction in wild-type rats. Brain. 2021;**144**: 1853-1868. DOI: 10.1093/BRAIN/ AWAB061

[100] Wang X-J, Ma M-M, Zhou L-B, Jiang X-Y, Hao M-M, Teng RKF, et al. Autonomic ganglionic injection of *αsynuclein* fibrils as a model of pure autonomic failure α-synucleinopathy. Nature Communications. 2020;**11**: 934(1)-934(13). DOI: 10.1038/s41467- 019-14189-9

[101] Shen Y, Yu WB, Shen B, Dong H, Zhao J, Tang YL, et al. Propagated αsynucleinopathy recapitulates REM sleep behaviour disorder followed by parkinsonian phenotypes in mice. Brain. 2020;**143**:3374-3392. DOI: 10.1093/ BRAIN/AWAA283

[102] Taguchi T, Ikuno M, Hondo M, Parajuli LK, Taguchi K, Ueda J, et al. *αsynuclein* BAC transgenic mice exhibit RBD-like behaviour and hyposmia: A prodromal Parkinson's disease model. Brain. 2020;**143**:249-265. DOI: 10.1093/ BRAIN/AWZ380

[103] Taylor TN, Caudle WM, Shepherd KR, Noorian AR, Jackson CR, Iuvone PM, et al. Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity. The Journal of Neuroscience. 2009;**29**:8103-8113. DOI: 10.1523/JNEUROSCI.1495-09.2009

[104] Irwin DJ, Abrams JY, Schonberger LB, Leschek EW, Mills JL, Lee VMY, et al. Evaluation of potential infectivity of Alzheimer and Parkinson disease proteins in recipients of cadaverderived human growth hormone. JAMA

*Early Diagnosis of Parkinson's Disease: Utility of Animal Models DOI: http://dx.doi.org/10.5772/intechopen.107887*

Neurology. 2013;**70**:462-468. DOI: 10.1001/JAMANEUROL.2013. 1933

[105] Strohäker T, Jung BC, Liou S-H, Fernandez CO, Riedel D, Becker S, et al. Structural heterogeneity of *α-synuclein* fibrils amplified from patient brain extracts. Nature Communications. 2019; **10**:5535(1)-5535(12). DOI: 10.1038/ s41467-019-13564-w

[106] Decressac M, Kadkhodaei B, Mattsson B, Laguna A, Perlmann T, Björklund A. α-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. Science Translational Medicine. 2012;**4**:163ra156(1)-163ra156(15). DOI: 10.1126/scitranslmed.3004676

[107] Kirkeby A, Barker RA. Parkinson disease and growth factors—Is GDNF good enough? Nature Reviews. Neurology. 2019;**15**:312-314. DOI: 10.1038/S41582-019-0180-6

[108] The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia— PubMed n.d. Available from: https://pub med.ncbi.nlm.nih.gov/13869404/ [Accessed: July 14, 2022]

[109] Carlsson A, Lindqvist M, Magnusson T. 3,4- Dihydroxyphenylalanine and 5 hydroxytryptophan as reserpine antagonists. Nature. 1957;**180**:1200. DOI: 10.1038/1801200A0

[110] Bertler Å, Rosengren E. Occurrence and distribution of dopamine in brain and other tissues. Experientia. 1959;**15**: 10-11. DOI: 10.1007/BF02157069

[111] Ehringer H, Hornykiewicz O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Klinische Wochenschrift. 1960;**38**: 1236-1239. DOI: 10.1007/BF01485901

[112] Barker RA, Björklund A. Animal models of Parkinson's disease: Are they useful or not? Journal of Parkinson's Disease. 2020;**10**:1335-1342. DOI: 10.3233/JPD-202200

## **Chapter 5**
